PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 1
A PHASE 1, NON-RANDOMIZED, OPEN LABEL, SINGLE DOSE STUDY TO
EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF 
PF-06700841 IN PARTICIPANTS WITH RENAL IMPAIRMENT AND IN 
HEALTHY PARTICIPANTS WITH NORMAL RENAL FUNCTION
Investigational Product Number: PF-06700841
Investigational Product Name: Not Applicable (N/A)
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:N/A
Protocol Number: B7931048
Phase: 1
Short Title: Renal Impairment Study of PF-06700841
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by applicable law) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Chang es Table
Document History
Document Version Date Summary of Changes and Rationale
Original protocol 20 November 2019 Not applicable ( N/A)

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ..................... 7
1. PROTOCOL  SUMMARY .....................................................................................................8
1.1. Sy nopsis ....................................................................................................................8
1.2. Schema ......................................................................................................................8
1.3. Schedule of Activ
ities (SoA) .....................................................................................9
2. INTRODUCTION ...............................................................................................................13
2.1. Study  Rationa le.......................................................................................................13
2.2. Background .............................................................................................................13
2.2.1. Nonclinical Pharmacology ..........................................................................14
2.2.2. Nonclinical Pharmacokinetics and Metabolism
.........................................14
2.2.3. Nonclinical Safet y
......................................................................................14
2.2.4. Clinical Overview .......................................................................................15
2.2.4.1. Safet y Ove rview ........................................................................15
2.2.4.2. Summary  of PF -
06700841 Pharmacokinetics in Human..........17
2.3. Benefit/Risk Assessment
.........................................................................................18
3. OBJECTI
VES AND EN DPOINTS .....................................................................................20
4. STUDY DESIGN .................................................................................................................20
4.1. Overall Design .........................................................................................................20
4.2. Scientific Rationale for Study  Design .....................................................................25
4.3. Justification for Dose ..............................................................................................26
4.4. End of Study  Definiti on ..........................................................................................26
5.STUDY POPUL ATION
......................................................................................................26
5.1. I nclusion Criteria .....................................................................................................27
5.1.1. A ll Participants ...........................................................................................27
5.1.2. Add
itional Inclusion Criteria for Health y Participant s with Normal 
Renal Function (Cohort 2 only ) ................................ ................................ .......27
5.1.3 .Addi tional Inclusion Criteria for Participant s with Impaired Renal 
Function (Cohort 1 and Cohorts 3 & 4 [ if applicable ]only)............................ 28
5.2. Exclusion Criteria....................................................................................................29
5.2.1. All 
Participants ...........................................................................................29
5.2.2. Additional Exclusion Criteria for Health y Participants with Normal
Renal Function (Cohort 2, only) ................................ ................................ ......32

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 45.2.3. Additional Exclusion Criteria for Participants with I mpaired Renal 
Function (Cohort 1and Cohorts 3 & 4 [if applicable] only )............................ 33
5.3. L ifesty le Consideration s
..........................................................................................33
5.3.1. Meals and Dietary  Restrictions ...................................................................33
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................34
5.3.3. Activity .......................................................................................................34
5.3.4. Contraception ..............................................................................................34
5.4. Screen Failures ........................................................................................................35
6. STUDY INTERVENTIO N
..................................................................................................35
6.1. Study  Interventions Administered ...........................................................................35
6.1.1. Administration ............................................................................................35
6.2. Preparation/Handling/Storage/Accountability ........................................................36
6.2.1. Preparation and Dispensing ........................................................................37
6.3. Mea sures t
o Minimize Bias: Randomization and Blinding.....................................37
6.3.1. Allocation to I nvestigational Product .........................................................37
6.4. Study  Intervention Compli
ance...............................................................................37
6.5. Concomitant Therapy ..............................................................................................37
6.5.1. Participants with Healthy  Renal Function (Cohort 2 Only )
.......................38
6.5.2. P articipants with Impaired Renal Function (Cohort 1 and Cohorts 3
& 4[if applicable]) ...........................................................................................38
6.6. D ose Modification ...................................................................................................38
6.7. I ntervention After the End of the Study ..................................................................38
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................39
7.1. Discontinuation of Study  Intervention ....................................................................39
7.2. Participant Discontinuation/Wit
hdrawal From the Study .......................................39
7.3.Lost to Follow - up ................................ ................................ ................................ ....40
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ............................... 40
8.1. Efficacy  Assessments ..............................................................................................41
8.2. Safet y Assessments .................................................................................................42
8.2.1. Phy sical Examinations ................................................................................42
8.2.2. Vital Signs ..................................................................................................42
8.2.2.1. Tempe rature ..............................................................................42

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 58.2.3. Electrocardiograms.....................................................................................43
8.2.4. Clinical Safety La boratory Asse ssments ....................................................44
8.2.5. Pregnancy Testing ......................................................................................44
8.3. Adverse Events and Serious Adverse Events..........................................................45
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......45
8.3.1.1. Reporting SAEs to Pfizer Safety...............................................458.3.1.2. Recording Nonserious AEs and SAEs on the CRF...................46
8.3.2. Method of Detecting AEs and SAEs ..........................................................468.3.3. Follow-up of AEs and SAEs.......................................................................468.3.4. Regulatory Reporting Requirements for SAEs...........................................468.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................47
8.3.5.1. Exposure During Pregnancy......................................................478.3.5.2. Exposure During Breastfeeding ................................................478.3.5.3. Occupational Exposure .............................................................47
8.3.6. Medication Errors .......................................................................................47
8.4. Treatment of Overdose............................................................................................488.5. Pharmacokinetics ....................................................................................................49
8.5.1. Plasma for Analysis of PF-06700841 and M1............................................498.5.2. Urine for Analysis of PF-06700841 and M1 ..............................................50
8.6. Pharmaco dynamics..................................................................................................50
8.7. Genetics................................................................................................................... 50
8.7.1. Specified Genetics ......................................................................................50
8.8. Biomarkers ..............................................................................................................51
8.9. Health Economics ...................................................................................................51
9. STATISTICAL C ONSIDERATIONS ................................................................................51
9.1. Statistical Hypotheses .............................................................................................519.2. Sample Size Determination.....................................................................................519.3. Populations for Analysis .........................................................................................529.4. Statistical Analyses .................................................................................................52
9.4.1. Efficacy Analyses .......................................................................................53
CCI
PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 69.4.2. Safety Analyses ..........................................................................................53
9.4.2.1. Electrocardiogram Analyses......................................................54
9.4.3.1. Pharmacokinetic Analyses ........................................................54
9.5. Interim Analyses .....................................................................................................55
9.5.1. Data Monitoring Committee.......................................................................56
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................57
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............57
10.1.1. Regulatory and Ethical Considerations ....................................................57
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................57
10.1.2. Financial Disclosure .................................................................................5810.1.3. Informed Consent Process ........................................................................5810.1.4. Data Protection .........................................................................................5910.1.5. Dissemination of Clinical Study Data ......................................................5910.1.6. Data Qualit y Assurance ............................................................................60
10.1.7. Source Documents....................................................................................6210.1.8. Study and Site Closure..............................................................................62
10.1.9. Publication Policy.....................................................................................6210.1.10. Sponsor’s Qualified Medical Personnel .................................................63
10.2. Appendix 2: Clinical Laboratory Tests .................................................................64
10.2.1. Hepatitis B and C Testing Algorithm and Full Eligibility Criteria ..........6510.2.2. Tuberculosis Testing.................................................................................66
10.2.2.1. Purified Protein Derivative Test..............................................66
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................67
10.3.1. Definition of AE .......................................................................................6710.3.2. Definition of SAE.....................................................................................6810.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................6910.3.4. Reporting of SAEs....................................................................................72
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................................74CCI
PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 710.4.1. Male Participant Reproductive Inclusion Criteria ....................................74
10.4.2. Female Participant Reproductive Inclusion Criteria.................................7410.4.3. Woman of Childbearing Potential (WOCBP) ..........................................7510.4.4. Contraception Methods.............................................................................76
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ........80
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................8210.8. Appendix 8: Abbreviations ...................................................................................84
11. REFERENCES ................................................................................................................. .88
LIST OF TABLES
Table 1. Renal Function Categories by eGFR Ranges ...........................................21Table 2. Criteria to Establish Stable Renal Function..............................................24Table 3. Plasma PK Parameters..............................................................................55Table 4. Urine PK Parameters ................................................................................55Table 5. Protocol-Required Safety Laboratory Assessments .................................64CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 81.PROTOCOL SUMMARY
1.1.Synop sis
Not Applicable .
1.2.Schema
Not Applicable .

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 91.3. S chedule of Activ ities (SoA)
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the prot ocol for detailed information on each procedure and assessment required for compli ance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in addition to those listed 
in the SoA table , in order to conduct evaluations or 
assess ments required to protect the well -being of the participant .
Visit IdentifieraScreeningbDay -1bDay 1 Day 2 Day 3 Day 4 Follow -up 
ContactEarly Termination/
Discontin uation
(DC)Day -28 to Day -2
Days Relative to Day 1 S1 S2 28-35 Daysc
Informed consent X
Admission to CRU X
Confinement to CRU X    X
Inclusion/exclusion criteria X X
Medical history X X
DemographydX
Physical examinationeX X X
Height and weight assessmentfX X X Xg
Safety laboratory tests (blood and 
urine)hX XiX X XgX
eGFR asses smentjX X X Xg
QuantiFERON®-TB Gold Test or 
PPD skin testkX
Illegal drug/ tobacco/alcohol use X X
Urine alcohol test or alcohol 
breath testX X
Urine or serum pregnancy test 
(WOCBP only)X X X X
Contraception checklX X X X X
Serum FSH in post -menopausal 
females amenorrheic ≥12 months 
and under 60 years of ageX
Urine drug screen X X
Single supine 12-Lead ECG X XmX X

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 10Visit IdentifieraScreeningbDay -1bDay 1 Day 2 Day 3 Day 4 Follow-up 
ContactEarly Termination/
Discontinuation
(DC)Day -28 to Day -2
Days Relative to Day 1 S1 S2 28-35 Daysc
Vital signs (supine BP, pulse 
rate) and temperatureXXX X
HIV, HBsAg, HBcAb, HCVAb 
testingnX
Investigational productadministrationX
Plasma PK for PF-06700841 and 
M1XXXX X
Urine PK for PF-06700841 and 
M1XXXX
 
Prior/concomitant treatments X X X →→→ XX X
CRU discharge X
Serious and nonserious adverse 
event monitoringXXX →→→ XX X
Abbreviations: →= ongoing/continuous event; BP = blood pressure; DC = discontinuation; eGFR = estimated glomerular filtration rate; HBcAb = hepatiti s B core antibody; 
HBsAg = hepatitis B surface antigen; HCVAb = hepatitis C antibody; HIV = human immunodeficiency virus; CRU = clinical research uni t; ECG = electrocardiogram; 
FSH = follicle-stimulating hormone; PK = pharmacokinetic; PPD = purified protein derivative; QFT-G = QuantiFERON®-TB Gold; S1= Screening Visit 1 ; S2= Screening 
Visit 2 ; WOCBP = women of childbearing potential; M1 = a major metabolite of PF-06700841.CCI
PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 11Visit IdentifieraScreeningbDay -1bDay 1 Day 2 Day 3 Day 4 Follow-up 
ContactEarly Termination/
Discontinuation
(DC)Day -28 to Day -2
Days Relative to Day 1 S1 S2 28-35 Daysc
a.Day relative to start of study treatment (Day 1).
b.Screening will consist of 2 CRU outpatient visits (Screening Visits 1 and 2) between 3 to 14 days apart, with the 1st screening vi sit occurring within 28 days 
prior to investigational product administration (Day 1).  The 2nd screening visit is only to demonstrate stable renal function w ith difference between eGFRs 
at Screening visit 1 (S1) and Screening visit 2 (S2) required to be ≤25% of the value obtained at S1. If participant meets all screening criteria at S2 visit, and 
Day -1 visit can be performed immediately, the participant may be admitted to the unit at conclusion of S2 visit.  Other screen ing procedures completed 
during the first visit (S1) do not need to be repeated.  See Section 4.1 for outpatient visit screening schedule.
c.Contact may occur via telephone contact and must occur 28 to 35 days from administration of the investigational product or from the time of early 
termination/discontinuation. If participant demonstrates an increase of >25% in serum creatinine from Day -1 to Day of discharge , he or she will be asked 
for a follow-up visit to collect eGFR.
d.Demographics will include race, age and gender.
e.Complete physical examination at Day -1, Day 4, and early termination.  Limited physical examination at any time point as deemed  necessary by the 
investigator.
f.Height to be obtained at S1 only, weight to be obtained at S1, S2 and Days -1.
g.Only when the participant demonstrates an increase of >25% in serum creatinine from Day -1 to Day of discharge. Only serum crea tinine and weight 
information will be collected for eGFR assessment. 
h.Safety laboratory assessments include chemistry, hematology and urinalysis (and microscopy, if needed) and will be performed at  S1, on Day -1, Day 4 and 
early termination day.  All the assessments must be collected following at least a 4 hour fast.  
i.Serum creatinine only will be assessed on S2 for eGFR assessment.
j.To confirm eligibility, participants must have stable renal function defined as ≤25% difference for eGFR values at S2 compared to the value at S1.  The 
average of the 2 screening eGFR values will be used for participant stratification and group assignment (provided stable renal fu nction is still demonstrated).
If the renal function stability criterion is met but the renal function classification category changes between S1 eGFR and the  average of the S1 and 
S2 eGFRs, the eGFR measurement at Day -1 will also be used to determine the appropriate group classification category using an a verage of all 3 eGFR 
values, to determine whether the participant will be eligible for enrollment. The Day -1 eGFR value will be used for PK analysis .  The eGFR determination 
will utilize the 4-variable MDRD equation. A follow-up eGFR will be  collected at Day 28 (with window of +3 days to allow for holi days) for any participant
who demonstrates an increase of >25% in serum creatinine from Day -1 to Day of discharge.
k.If QFT-G test cannot be performed, or if results are indeterminate, participants may be screened using PPD Tuberculin Test (Man toux method), with 
approval of medical monitor.
l.Confirmation of appropriate use only.
m.Triplicate 12-lead ECG will be performed at 0 hr pre-dose on Day 1.  Single 12-lead ECG will be collected at 1, 3, and 6 hr post-d ose on Day 1.  
n.HBsAb will be performed as reflex testing for any participant who is HBsAg negative and HBcAb positive ( Section 10.2.1 ).  HCV RNA will be performed 
as reflex testing for any participant who is HCV Ab positive ( Section 10.2.1 ).
 CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 12Pharmacokinetic Sampling Sch ema
Visit Identifier 
Study Day1 2 3 4
Hours Before/After Dose 0a0.5 1 2 3 4 6 8 10 12 24 36 48 72
Investigational product
administrationX
PK blood samplingbX X X X X X X X X X X X X X
PK urine collectioncX         XX X
Abbreviation: = ongoing/continuous event, PK = pharmacokinetic.  
a. Predose sample collection.
b. Blood samples are to be collected for plasma PK assessment of both PF -0670 0841 and M1.
c. Urine collections during interval s of ≤24, >24 and ≤48, and >48 and ≤72hours after dosi ng on Day 1 . During the subsequent designated urine collection intervals ([0- 24], 
[24-48], and [48-72] hours post dose), participants will void ALL urine produced during the designated collection interval, including a forced voi d at th e end of the collection 
interval, directly into pre -weighed urine collection container. Urine sam ples will be analyzed using a validated analytical method in compliance with Pfizer SOPs , only if it is 
determined by the study team that there is a need to d o so, based on revie w of PF -06700841 and M1 plasma PK results.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 132.INTRODUCTION
PF-06700841 is a potent ty rosine kinase 2 (TYK2)/Janus kinase (JAK) 1 inhibitior that is 
currentl y being developed for the treatment of patients with inflammatory diseases, incl uding 
systemic lupus erythematosus (SL E), psoriatic arthritis (PsA) , psoriasis (PsO), alopecia 
areata (AA), vitiligo ,inflammatory  bowel disease (IBD) , hidradenitis suppurativa (HS) and 
atopic dermatitis (AD) .
2.1.Study Rationale 
In vitro and in vivo metaboli te profiling suggest ed that the primary  clearance mechanism for 
PF-
06700841 wascytochrome P450 (CYP450 )mediated oxidation. The contribution of 
individual CYP450 involved in t he metabolism of PF- 06700841 (1 µM) was assessed in a 
preliminary  reaction phen otyping study  using a human hepatocy te relay  method. Greater 
than 88% of the PF -06700841 metabolism observed was attributed to CYP450 with CYP3A4 
identified as the maj or contributor ( fraction metabolized [ fm]= 0.62) . In the first in human 
study , B7981001, u rinary recovery  of PF -06700841 was low, with < 16% of the dose 
recovered unchanged in urine across all doses (geometric mean Ae τ% of 8.9% to 15.5%), 
indicating that the renal pathway  play s a minimal role in PF -06700841 excretion.  
Evidence suggests that the pharmacokinetic s (PK)of drugs that are not on ly excreted b y the 
kidney  can be affected by  renal impairment through inhibiti on of pathways of hepatic and gut 
drug metabolism and transport.1  Consequently , recent European Medicin es Agency  (EMA)
guideline s
suggest that renal impairment studies be conducted in patients with decreased 
renal function for nearl y all small molecules, even if the drug or its active metabolite is not 
primarily  eliminated by  the kidney s.2The revised Food and Drug Administration (FDA) 
Draft Guidance on renal impairment studies also recommends that a PK study  be conducted 
in participants with renal impairment when the drug is like ly to be used in patients with 
impa ired renal function.1
PF-06700841 is intended for chronic use in patients, some of whom may  have some degree 
of impaired renal function. Therefore, the purpose of this study  is to characterize the effect 
of renalimpairment on the plasma PK of PF-06700841 .  Findings from this study will be 
used to develop dosing recommendations so that the dose and/or dosing interval may be 
adjusted appropriately  in the presence of renal disease.
2.2.Background
PF-06700841 is a dual TYK2/JAK1 inhibitor with a high selectivity  profile over other human
kinases. The clinical efficacy  of JAK1 inhibitio n with tofacitinib has been established in PsA
, 
PsO and in IBD.3,4,5PF-06700841 targets the JAK1 -dependent pathw ays, and in addition, 
inhibiting TYK2 i s expected to lower interleukin ( IL)-12, IL-23 and Ty pe I interferon (IFN) 
signaling to a greater degree tha n JAK1 inhibition alone.   Accumulating evidence indicates 
that the IL -
23/T help 17 (Th17) pathway  play s an important role in the pathology  of PsO, 
PsA, AAand IBD. Inhibition of both JAK1 and TYK2 is expected to provide greater 
therapeutic benefit in the treatment of plaque PsO, PsA, AA, AD, SL E, HS , vitiligo andIBD. 
In Stud y B7931001, PsO participant s receivi ng active treatment with PF- 06700841 (30 mg or 
100mg once dail y[QD] for 28 days) had clinically meaningful decreases in disease activity  

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 14as measu red b y Psoriasis Area and Severit y Index (PASI ; a validated PsO clinical disease 
activity  metric accepted by  regulatory  agencies).   Preli minary  safet y, efficacy , and 
pharmacod ynamics results from Study  B7931001 support further development of 
PF-06700841 in plaque PsO, PsA (based on the PsO data) and possibly  IBD. APhase 2 
study  B7931004 to assess the safet y and efficacy  ofseveral dose levels of PF -06700841 in 
participant s with moderate -to-severe chronic plaque PsO was completed
.  PF-06700841 is 
currentl yunder assessment in 4ongoing Phase 2 studies in AA(B7931005), ulcerative colitis
(UC) (B7981005), Crohn’ s Disease (CD) (B7981007) and SLE (B7931028). Ongoing and 
future studies with PF-06700841 explore doses up to 60 mg given QD .
2.2.1. Nonclinical Pharmacology
Details of the nonclinical pharmacology  of PF -06700841 can be found in the current 
Investigator Brochure ( IB).
2.2.2. Nonclinical 
Pharmacokinetics and Metabolism
Hepatic CYP450 enzy mes were implicated in the clearance of PF- 06700841 in initial parent 
drug conversion studies in rat, monkey , and/or human liver microsomes and hepatocy tes.
There was no evidence of aldeh ydeoxidase -media ted PF -06700841 metabolism in a human 
cytosol screen.  The contribution of individual CYP450 involved in the metabolism of 
PF-06700841 (1 µM) was assessed in a preliminary reaction phenot yping study  using a 
human hepatocy te relay  method. Greater than 88% 
of the PF -06700841 metabolism 
observed was attributed to CYP450 with CYP3A4 identified as the major contributor 
(fm=0.62). Huma n Absorption, Distribution, Metabolism and Elimination (ADME )study  
(B7931014) is on going todefinitively  assess elimination p athway s and metabolic profiles.
Additional information of the nonclinical PKand metabolism of PF -06700841 is available in 
the cur rent IB.
2.2.3.
Nonclinical Safety
No adverse findings were observed in oral repeat -dose toxicity  studies with PF -06700841 in 
rats and monkey s up to 6 and 9 months in duration
, respectivel y.  PF- 06700841 -related, 
non-adverse, target organs identified include the immune and hematol ymphopoietic systems 
(thymus, spleen, l ymph nodes, and bone marrow), cardiovascular s ystem 
(blood pre ssure, 
heart rate, corrected QTwave interval [QTc]), gastrointestinal tract (bod y weight and weight 
gain effects), and adrenal gland (va cuolation).  The findings in the thy mus, spleen, ly mph 
nodes, and bone marrow are consistent with the pharmac ological a ctivity  of PF -06700841.  
The no-observed -adverse- effect level ( NOAELs ) in the 6- and 9 -month toxicity  studies were 
45mg/kg/day  in rats (u
nbound Cmaxof 8280 ng/mL and area under the curve from time 0 to
24hours [ AUC 24]of 69,700 ng•h/mL) and 20 mg/kg/day  in monkey s (unbound maximum 
plasma concentration [Cmax] of 2260 ng/mL  and AUC 24of 10,700 ng•h/mL).   Adverse 
findings in the central nerv ous sy stem (decreased activity , mortalit y, prostration, 
convulsions) were observed at high systemic exposures in pregnant, but not in non-pregnant 
rabbits.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 15In oralembry o-fetal development studies in rats and rabbits, adverse PF -06700841 -related 
developmen tal effects occurred (lower embry o-fetal viability  and mean fetal body  weights, 
fetal skeletal malformations, external malformations).   The developmental NOAEL in rabbits 
was1mg/kg/day  (unbound C maxof 174 ng/mL  and AU C24of 608 ng•h/mL).
The development al NOAEL  in rats was not established and is <2 mg/kg/day  (unbound C max
of 482 ng/mL and AUC 24of 2240 ng•h/mL ), the lowest dose tested.  No effects on female 
reproductive organs, as assessed by  histopathologic examinatio n, were noted in either the rat 
or monkey  repeat -dose toxicity  studies.  PF -
06700841 is not mutagenic in bacterial reverse 
mutation assay s.  Alth ough PF -06700841 was positive for micronuclei formation in vitro 
(through an aneugenic mechanism), it did not induce micronuclei 
in vivo in rats at
55mg/kg/day  (unbound C max= 7730 ng/mL and AUC 24= 88,300 ng•h/mL ), the highest dose 
tested in the 1 -month oral toxicity  study .
Further details of the nonclinical safet y program are provided in the current IB.
2.2.4. Clinical Overview
The sponsor’s clinical dev elopment program for PF-06700841 consists of 3 completed 
Phase1 studies in healthy
 participant s and PsO participant s (B7931001 , B7931009 and 
B7931010), 1complete Phase 2 study in PsO (B7931004 ), and is currently  under assessment 
in 6ongoing Phase 2 studies in AA (B7931005), UC(B7981005) ,CD(B7981007) and SLE
(B7931028) ,vitiligo (B7981019), PsA (B7931030), a nd 1 planned Phase 2 study  in HS 
(C2501007).  In addition, 2 Phase 1 studies in healthy  participant s are clinically  complete an d
preparation of the clinical reports including a study  to assess effect of PF -06700841 on QTc 
interval (B7931019 ) and a human AD ME study  usin g 14C microtracer (B7931014) .A drug 
interaction study  with a potent CYP3A4 inhibitor, itraconazole (B7931033) is ongoing .  The 
studi es described above have all used oral administration of PF
-06700841.  The topical 
development program consist s of 1 completed Phase 1 study  (B7931029), and 2 ongoing 
Phase 2 studies in AD (B7931 022) and PsO (B7931023) . 
Included in this Clinical Overview are summaries of the results from onl y the clinically  
completed Phase 1 studies, B7931001
,B7931009, B7931010, B7931014 and B7931019,
Phase 2 study  in PsO, B7931004 and ongoing Phase 2 study  in AA with an interim analy sis 
study  result (B7931005).
2.2.4.1. Safety Ov erview
Overall, PF -06700841 was generally  well- tolerated in healthy  volunteers (B7931001,
B7931009, B7931010, B7931014, and B7931019); PsO (B7931001 and B7931004) and AA
participants (B7931005). There were no clinical meaningful findings in vital signs, s uicidal 
behavior or ideation, or potential Hy ’s Law cases reported during these studies.
Refer to the IBfor more details on the clinical safety  informat ion with PF -06700841.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 162.2.4.1.1. Phase 1 Studies
In first-in-human ( FIH)study  B7931001, the most commonly  reporte d all causality  
treatment -emergent adverse events ( TEAEs) across active participants in both healthy  
voluntee rs and PsO participants were blood creatinin e increased, leading to 5 withdrawals in 
the study .Participants in the multiple ascending dose [MAD] and PsO periods that had 
increased serum creatinine ( SCr) ≥0.3 mg/dL did not demonstrate significant changes in S 
Cystatin -C based estimated glomerular f iltration rate ( eGFR ), suggesting that the change in 
creatinine -based eGFR might be caused b y changes in renal handling of creatinine, rather 
than by  alteratio n of renal function. The most frequently  reported laboratory abnormalities 
were increases in low-density  lipoprotein ( LDL ), serum creatinine, and decreases in 
neutrophil counts in participants receiving PF-06700841 during single ascending dose 
[SAD] /MAD a nd psoriatic period. Neutrophil count decreased (r eported in 4 participants 
during the MAD per iod), leading to 3 withdrawals in the study .
In B7931009 , B7931010 and B7931014 studies , oral administration of PF -06700841 was 
well-tolerated in healthy  partici pants investigated in the study .There were no dea ths, serious 
adverse events ( SAEs ), severe adverse events ( AEs), discontinuations due to AEs, or dose 
reductions or temporary  discontinuations due to AEs during this study .There were no 
clinically  signif icant findings observed in laboratory parameters, v ital signs, 
electrocardiogram ( ECG )parameters.
A formal through QT study  (B7931019) suggested PF -06700841 has a small effect on QT 
prolongation. Following a single dose of 200 mg PF -06700841, the maximum
placebo- corrected QT interval corrected using Fridericia’s correction factor ( QTcF )change 
from baseline was observed at 3 hours post-dose with mean of 14.6 ms and 90% confidence 
interval (CI) of (12.4, 16.8 ms). As expected, the maximum mean change in Q TcF observed 
following administration of 400 mg mox ifloxacin was 13.8 ms (90% CI:11.6, 16.0 ms). 
Despite QTc effect observed after single doses of PF-06700841 200 mg and moxifloxacin 
400 mg, there were no clinically  significant findings in ECG categorical analy ses in that QTc 
change from baseline >60 msec or QTc absolute value >500 msec w as not observed. Based 
on the concentration -QTcF anal ysis, the primary  anal ysis defined in this study , the estimated 
QTcF increase at predicted C maxof PF -06700841 60 mg QD, the highest clinical dose used in 
ongoing Phase 2 studies, is approximately  8.8 m s with the upper bound of 90% CI (10.2 ms) 
slightly  exceeding 10 ms threshold.
2.2.4.1.2. Phase 2 Studies 
A total of 189 PsO participant s out of 212 enrolled in B7931004 were exposed to at least 
1dose of PF -
06700841 during the stud y.  The proportion of participant s with all -causalit y
TEAEs was comparable across all 
treatment arms but numerically  higher in the active 
treatment arm s (64.0% to 76.7%) than the placebo group (56.5%).  Th e majority  of 
participant s in all treatment arms ex perienced mild or moderate all- causality TEAEs, and 
only 5.2% experienced severe all- causality  TEAEs.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 17Overall, there were no dose- dependent increases in the all -causality  TEAEs.  Most TEAEs in 
the Infectio n and Infestation class were mild to moderate excep t 1participant who had 
2serious infections after taking a single dose of 60 mg PF -06700841 on D ay1.  One 
(1)participant in the 30mg QD to 100 mg once a week (QW) group had squamous cell 
carcinoma of s
kin reported on Day 2 of treatmen t.  One (1)partic ipant in the 30 to 10 mg 
group was confirmed to be pregnant after being in the study  for 42days and was 
discontinued from the study
 with obstetrical ultrasound demonstrating fetal cleft lip.
Decreased reticulocy tes, hemoglobin, and neutrophils were observed in the participants on
active treatment during 4 -week induction phase and returned to ward baseline level during 
8-week maintenanc e phase.  Increases in serum creatinine from baseline were observed in al l 
active treatment arms with no association of chan ge in cy statin C based renal function 
measurement .  Other commonly  reported laboratory  abnormalities were elevation of LDL 
with no clinical meaningful changes in LDL/
high density  lipoprotein ( HDL )ratio.  C reatine 
kinase (CK) lev els >10 × upper limit of normal (ULN) were observed in two participants 
without adverse event (AE).  One moderate AEof CK -myoglobin incre ase was reported b y 
oneparticipant in the 30 to 10 mg QD group during the induction period, w hich was 
considered to be re lated to the investigat ional product by the investigator.  No participant was 
discontinued from the study  due to CK elevation.
In Study B7931005, 47 AAparticipant s were exposed 
to at least 1dose of PF -06700841.  
The most commonly  reported TEAEs in the ac tive treatment arm was in the Infections and 
Infestations sy stem organ class ( SOC )(51.1% in the investigational product vs 40.4% in the 
placebo).  Other TEAEs were Gastrointestinal Disorders (23.4% in the investigational 
produc tvs 25.5% in the placebo).   Most of those TEAEs we re mild.  There were 2
participant s receiving PF -
06700841 that experienced rhabdom yolysis after strenuously  
exercising during the study , which were not considered to be related to the investigational 
produ ct by investigator assessment.   Three participants experienced mild decreases in 
neutrophils, one participant had a mild reduction in platelets, and one participant a mild 
reduction in ly mphocy tes.
2.2.4.2. Summary of PF -06700841 Pharmacokinetics in Human
In Stud y B7931001, following single oral doses of 1 mg to 20 0mg under fasted conditions, 
PF-06700841 was absorbed rapidl y with median time to maximum concentration (T max)of 
1hour or less.  Mean terminal half -life ( t½) ranged from 3.8 to 7.5 hours.  In general, both the 
area under the concentration -time curve fro m time 0 to infinity  
(AUC inf) and Cmaxappeared 
to increase proportionally  with dose from 1 mg to 100 mg.  Increases from 100 mg to 200 mg 
appear more than dose proportional, especiall y for AUC inf.
On Day 10 of multiple dose administration, PF -06700841 was absorbed rapidly  with median 
Tmaxof 1 to 1.5 hours or less across the entire range of doses, from a total daily  dose of 
10
mg up to 175 mg.  Following attainment of C max, the disposition of PF -06700841 w as 
similar with that observed following single dose administration.  Mean t½ranged from 4.9 to 
10.7
hours.  Both area under the concentration- time curve from time 0 to time (AUC ) and 
Cmaxgenerall y appeared to increase proportionall y with dose from 10 mg to 100 mgQD, 
with a trend towards greater than proportional increase from 100 mg to 175 mg QD.  

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 18Accumulations, following once dail y dosing, ranged from 1.1 to 1.4 for AUC tand 0.8 to 
1.1for Cmax.  The urinary recovery  of unchanged (Ae %) PF -06700841 on Day 10 across all 
doses ranged from 8.9% to 15.5%.  Following multiple dose administration of PF -
06700841 
to participants with PsO for 28 -days, the overall exposure observe d was comparable to that in 
healthy  participants at same dose level.
The relat ive 
bioavailability  ofa solid dose formulation of PF -06700841 relative to a solution 
and the food effect on the solid dosage formulation was also evaluated.  Following sin gle or al 
100mg doses under fasting conditions, median Tmaxwas 0.5 hours for the ta bletformulation 
and 1.0 hours for the solution.  The ratios of adjusted geometric means between tablet versus 
solution formulation were 96.2% for AUC infand 94.3% for C max.  Whe n the tablet was 
administered following a high fat meal, Tmaxwas delay ed with median of 4.0 hours and the 
AUC infand Cmaxwere 82.3% and 64.3%, respectively of those observed when tablets were 
given fasted.
In Study  B7931009, higher exposure in Japanese participants (n=6) observed compared to 
that in non -Japanese 
participants from B793 1001 stu dy: the mean steady  state C maxwere 
1114 (14%) vs 734.1 (29%) ng/mL  and steady  state mean AUC 24were 9888 (33%) vs 
6089 (38%) ng•h/mL for Japanese participants and no n-Japanese participants respectivel y 
after multiple doses of 100 mg QD.
In the recently clinicall y completed ADME stud y B7931014, t he preliminary  metabolite 
profiling anal ysis identified a single major metabolite M1 (PF -
06802530). PF-06802530 is 
primarily  formed via CYP3A -mediated h ydrox ylation of PF -06700841 and mainly  
eliminated v ia renal excretion.
B7931004 study  was recen tly completed.  In this study , PK samples were collected at 
pre-dose and/or 0.5 hours post -dose at each visi t over 12
-week treatment. Post-dose samples 
were also collected up to 4 hours at Weeks 4 and 12.  Plasm a concentrations of PF -06700841 
observed wer e as expected based on PK in PsO participants.
2.3.Benefit/Risk Assessment
PF-06700841 is not expected to provide an y clinical benefit to health y participants or 
participants with renal impairment in this study .  This study is designed primarily  to 
characteriz e the effect of renal impairment on the plasma 
PKof a single dose of 
PF-06700841.  The data from this study  are expected to provide t he basis for development of 
dosing recommendations for target patient populations who may  have renal impairment.  
Based on the data in Phase 1 program, the clinical safet y profile of PF -06700841 appears to
be acceptable at dosages up to 200 mg single dose and 175 mg repeated daily  doses 
administered orall y.  Based on the clinical experience with PF -06700841 and/or other JAK 
inhibitors (eg, Xeljanz®[tofacitinib], Jakafi®[ruxolitinib], baricitinib, filgotin ib and 
upadacitinib), anticipated risks with PF -
06700841 include: (1) an increase in susceptibility  to 
infection, (2) viral reac tivation, (3) malignancy  and ly mphoproliferative disorders, 
(4)alterations in laboratory  parameters, including: decreased neutr ophil counts, decreased 
lymphocy te counts, decreas
ed hemoglobin level, decreased platelet counts, alterations in the 

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 19hepatic tra nsaminases and serum creatinine.  There was one AE of herpes zoster infection in 
a PsO participant treated with 100 mg PF -067008 41 for 4 weeks.  Laboratory  changes can be 
managed by monitoring criteria as well as adjustment of the inclusion/exclusion crite ria.
Based on in vitro data, moderate and strong CYP3A inhibitors or inducers, strong 
P
-glycoprotein ( P-gp)inhibitors, P -gp sub strates and substrates of organic cation transport
2 (OCT2)/ multidrug toxin extrusion protein (MATE )with a narrow therapeutic i ndex, will be 
prohibited during PF -06700841 treatment periods in ongoing P hase 2 studies to minimize 
any potential significant drug interaction.   Detailed information about in vi tro assessments on 
drug metabolism, enzy me phenot ypeand drug -
drug interaction canbe found in the IB.
More detailed information about the known and expected benefits and risks and reasonabl y 
expected adver se events of PF -06700841 may  be found in the IB , which is the single 
reference safet y document (SRSD) for this study .

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 203. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary: Primary:
•Part 1: To evaluate the effect of severe renal 
impairment on the PK of PF-06700841 andM1, a major metabolite of PF-06700841,following single oral dose administration.
•Part 2 (if applicable): To evaluate the effect of 
moderate and mild renal impairment on the 
PK of PF-06700841 and M1 following singleoral dose administration.•Plasma PF-06700841 and M1 PK parameters: 
C
maxand AUC inf.
Secondary: Secondary:
•To evaluate the safety and tolerability of 
single oral dose of PF-06700841 in 
participants with renal impairment and in 
healthy participants with normal renal function.•Safety: treatment-emergent adverse events, 
clinical laboratory tests, vital signs, physical examination and ECGs.
 
 
 
 
  
 
 
 
 
 
  
 
 
4. STUDY DESIGN
4.1. Overall DesignThis is a Phase 1, non-randomized, open-label, single-dose, parallel-cohort study to 
investigate the effect of renal impairment on the plasma PK, safety and tolerability of PF-06700841 after single oral dose of 30 mg in approximately 2 clinical research units (CRU).  A staged approach, as outlined in detail below, will be followed in the study.
Participants will be selected and categorized into normal renal function or renal impairment 
groups based on their estimated glomerular filtration rate (eGFR) as shown in Table 1 .CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 21Table 1. Renal Function Categories by eGFR Ranges
Cohort Renal Impair mentaEstimated eGFRb (mL/min) Number of Participant s
1 Severe Renal Impairment <30 and not requiring dialysi s 8
2 None (Normal) ≥90 8
3 Moderate Renal Impairment ≥30 to <60 8
4 Mild Renal Impairm ent 60 –89 8
a.Stages of renal impairment are based on Kidney Disease Outcomes Quality Initiative (KDOQI ) Clinical 
Practice Guidelines for Chronic Kidney Disease (CKD) .1
b.Estimate of eGFR based on Modification of Diet in Renal Disease (MDRD) formula.  The average of the 
2screening eGFR value will be used for group assignment.
Step 1: eGFR (mL /min/1.73m2) = 175 × (S cr, std)-1.154 × (Age)-0.203 × (0.742 if female) 
× (1.212 i f African American) where S cr, stddenotes serum creatinine measured w ith a standardized 
assay.
Step 2: Convert the MDRD- derived, body surface area (BSA) -adjusted eGFR obtai ned above to 
absol ute eGFR (mL/min) for eligibility assessment using the following equation: 
eGFR (mL/min) = eGFR (mL/min/1.73m2) ×participant ’s BSA where BSA is calculated as 
BSA= (Weight0.425×Height0.725) ×0.007184.
Part 1: A total of approximatel y 16 participant s will be enrolled in Part 1; approximately  
8participan ts with severe renal impairment (Cohort 1) and approximately  8 with normal 
renal function (Cohort 2) to ensure at least 6 evaluable participants in each group . 
Participant s from the s evere renal impairment group will be recruited first. The 
demographics will be poo led across stud y sites to determine an average value for age and 
weight in the severe impairment group . Subsequently , the healthy  participants will be 
recruited later such that each participant ’s age is within ±10 years and weight is within 
±15kg of the mean of severe renal impairment group . 
An attempt will be made to maintain a
similar male/female ratio composition between groups .Care will be taken when recruiting 
the health y participant s such that the entire group is not of substantially different age orof 
substantially  different body weight than the severe lyrenally  impaired participant s.  Approval 
from the sponsor must be obtained befor eproceeding with dosing health y participant s with 
normal renal function.
If there are participants who withdraw or discontinue treatment from the normal or severe 
renal impairment groups and who are considered to be non-evaluable with respect to the 
primary  PK objective, additional participants can be enrolled at the discretion of the sponsor.
Criteria to proceed to Part 2: After statistical evaluation of results from Part 1 (see
Section 9.4 ), Part 2 will be conducted if the point estimate of PF-06700841 or M1 area under 
the concentratio n-time curve from time 0 to infinity ( AUC inf)geometric mean ratio (GMR) 
for the severe renal impairment group (compared to the normal group as control) is ≥1.5.  I f 
th
iscriterion is not met, the study will stop after Part 1.
Part 2: Based on whether the decision criterio n to procee d to Part 2 is met, approximately  
8participant s each with moderate (Cohort 3) and mild (Cohort 4) renal impairment will be 
enrolledto ensure at least 6 evaluable participants in each group . As in Part 1, renal 
impairment classification will be based on eGFR .Heal thy participant s will not be enrolled in 

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 22Part 2. Health y participants from Part 1 will be used as the control group for the modera te 
and mild impairment participants. 
When recruiting the Part 2 participants, attempts to match the entire group to the par ticipants 
in Part 1 with respect to age, gender and bod y weight will be made. Other demographics, 
such as race and e thnicity , may  be considered for matching the Part 1 a nd Part 2 population s
when possible. Statistical considerations to account for an y differences in demographics are 
detailed in Section 9.4 .
As in Part 1, if the re are participants who withdraw or discontinue treatm ent from the 
moderate or mild impairment group and who are considered to be non -evaluable with respect 
to the primary  PK objective, additional participants can be enrolled at the discretion of the 
spons or. 
For both Parts 1 and 2 : All participant sin both normal and renal impairment group swill 
provide informed consent and unde rgo Screeni ng evaluations to determine their eligibility .  
Participant screening for participation in this study  will consist of 
2CRU outpatient visits not 
more than 14 days apart (b ut at least 3 days apart), with the 1stscreening visit occurring 
within 28days prior to administration of investigational product .  Each participant will be 
admitted to the research unit on Day  
-1 (at least 12 hours prior to the dosing of PF-06700841
on Day 1).  An eGFR value for group placement (provided stable renal functio n is still 
demonstrated) will be obtained bythe average of the 2 screening values (using the 
Modification of Diet in Renal Disea se [MDRD ]equation) .If the renal function stability  
criterion is met but the renal function classification category  changes b etween 
Screening 
Visit 1(S1)eGFR and the average of the S1 and Screening Visit 2 (S2) eGFRs, the eGFR 
measurement at Day  -1 will also be used to determine the appropriate group classification 
category  using an average of all 3 eGFR values, to determine wh ether the p articipant will be 
eligible for enrollment .
Eligible participant s will be admitted to the CRU on Day  -1 and will be c onfined in the CRU 
until Day  4. If participant meets all screening criteria at S2 visit, and Day -1 visit can be 
performed imm ediately , t
he participant may  be admitted to the unit at conclusi on of S2 visit.  
On the morning of Day 1,the participants willreceive a 30 mg single dose of PF-06700841
after a fast of at least 10 hours. No food will be allowed for at least 4 hours po st-dose. Serial 
blood and urine samples at specified intervals (as per Schedule of Act ivities ) will be 
collected for 72hours post-dose for plasma and urine PK assessments, prior to discharge 
from the CRU on Day 4.The eGF Rvalue will be determined on Day  -1andwill be used in
PK analy sis.  
Safety  assessments (as specified in the Schedule of Activities ) will be performed during S1, 
on Day  -1 and prior to dosing on Day 4. Only  serum creatinine will be addi tionally  assessed 
on S2 for eGFR estimation. Physical examinations, vital sign measurement s, and clinical 
laboratory  tests will be conducted and AEs will be monitored as per Schedule of Activities to 
assess safet y.  The total participation time (ie, CRU confinement time for study  procedures) 
for each participant in this study is approximately  4nights/ 5days (excluding screening &

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 23Follow -Up contact).  Participants will have a follow -up phone contact 28-35days after last 
IPadministration to assess for AEs.If participant demonstrates an increase of >25% in SCr
from Day  -1 to Day  of discharge, he or she will be asked for a follow -up visit to collect 
eGFR.
All procedures and th eir timelin es follow the Schedule of Activities.  
Calculation of eGFR:
The following MDRD equation will be used to calculate eGFR (Scr, std denotes serum 
creatinine measured with a standardiz ed assay  for serum cr eatinine):
eGFR (mL/min/1.73m2) = 175 × (S cr, std)-1.154 × (Age)-0.203 × (0.742 if female) 
× (1.212 if African American)
Note that the value of eGFR, which is directl y obtained from the lab oratory or calculated 
using the equation above, is generall y normalized toan average bod y size of 1.73 m2for 
diagnosis, prognosis and treatment of renal disease.  In terms of clearance of ren ally filtered 
drugs ( including secreted drugs), renal elimination capacity  is related to absolute glomerular 
filtration rate (
GFR)in mL/m in. To use the MDRD -derived, bod y surface area 
(BSA) -adjusted value of eGFR to obtain absolute glomerular filtration rate (GFR )(mL/min)
for renal disease classification or participant assignment into different renal disease groups, 
this value should be m ultiplied by  the individual participant ’s BSA (ie, measured 
BSA/1.73 m2).The BSA of an individu al can be calculated by the following formula as 
described below:
BSA = ( Weight0.425×Height0.725) × 0.007184
In summary , GFR in mL/min calculated as below wi ll be used for renal impairment group 
placement:  
Step 1: Obtain the MDRD -derived eGFR:
eGFR (mL /min/1.73m2) = 175 × (Scr, std)-1.154 × (Age)-0.203 × (0.742 if female) 
×(1.212 if African American) where S cr, std denotes serum creatinine measured with a 
standardized assay .
Step 2: Convert the MDRD -derived, BSA -adjusted eGFR obtained above to absolute GFR 
(mL/min) for el igibility  assessment using the following equation: 
eGFR (mL/min) = eGFR (mL /min/1.73m2) ×participant ’s BSA where BSA is 
calcu lated as BSA= (Weight0.425×Height0.725) × 0.007184.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 24Creatinine clearance ( CL CR) will also be e stimated from a spot serum creatinine measurement 
using the following Cockcroft- Gault (C -G) equation:
CL CR(mL/min) = (140 – age [years])× total bod y weight ( kg) × (0.85 for females)
72 × serum creatinine (mg/dL)
Note that eGFR calculated by  the MDRD equation will be used for categoriz ation of degrees 
of renal impairment.  Nevertheless, renal function will be estimated using both C -G and 
MDRD equations in this study and dose recommendations will be made using both C- G and 
MDRD equations .
To be enrolled into the study , participant must demonstrate stable renal function, with 
≤25% change based upon screening S1 eGFR and screening S2 eGFR (calculated by  the 
MDRD equation). The S2 eGFR assessment should be performed between 3 to 14 day s after 
the S1 eGFR assessment. The average of these 2 eGFR values will be used for group 
placement based on the renal function classification category
.
If the renal function stability  criterion is met and the renal function classificati on 
category  remains the same between S1 eGFR and the average of the S1 and 
S2eGFRs, participant will be eligible for enrollment.
If the renal function stability  criterion is not met, participant will be screen failed.
If the renal function stability  crite rion is met but the renal function classification 
category  changes betwee n S1 eGFR and the average of the S1 and S2 eGFRs, the 
eGFR measurement at Day
 -1 will also be used to determine the appropriate group 
classification category  using an average of all 3 eGFR values, to determine whether 
the participant will be eligible for e nrollment.  
In case of screen failure related to eGFR stability  and/or change in the renal function 
classification category , participant may  be re -screened once after a 30- day period , provided 
that the initial screen failure is not due to an Inclusion/Exc lusion criterion that results in 
permanent disqualification from enrollment (eg, medical history ).  This can be done onl y 
with sponsor’s approval.
Please see Table 2below regarding demonstr ation of stable renal function:
Table 2. Criteria to Establish Stable Renal Function
Renal function Measurem ent eGFR (mL/min) Criterion for stability
S1 G1
S2(Within 3 to 14 days after S1) G2 =|G2-G1|×100/G1a
If 
25%; stable
If >25%; not stable
Abbreviations: S1= Screening Visit 1; S2= Screening Visit 2.
a.Parenthesis of | | represents absolute values.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 254.2.Scientific Rationale for Study Design
This study is a phase 1,non-randomized, open -label, single -dose, parallel- group study  of 
PF-06700841 in participants with severe renal impairment and participants with normal renal 
impairment (Part 1) and in participants with mild and moderate renal impairmen t (Part 2), 
matched for age, bod y weight and, to the extent possible, for gender composition .  Details on 
age and bod y weight matching c riteria are specified in Section 4.1. 
Since PF -
06700841 is primarily  eliminated through a CYP450 mediated oxidation with 
CYP3A4 as the major contributor (fm = 0.62) and renal excr
etion as unchanged is minor 
(<16% ), a reduced study  design is proposed as suggested in the current draft guidance by  
FDA and EMA .2,6In the reduced study , only participants with severe renal impairment and 
participants with normal renal function will be studied first. Therefore, 
the effect of renal 
impairment on PF -0670084 1PK will be initially  evaluated in the renally  impaired population 
most likely  to be of impact. The impact of renal impairment on expression of CYP enzy mes, 
if any , is expected to be minimal and hence can also be evaluated in the severel y renall y 
impaire d population to estimate the degree of impact. If the stud y results confirm that severe 
renal impairment does not alter PK to an extent that warrants dosage adjustment, no further 
study  is warranted. If the results do not support such a conclusion, Part 2 will be conducted 
in participants with moderat eand mild renal impairment, based on the decision criterion 
outlined in Section 4.1.
Single dose PF -
06700841 PK appeared to be linear in the dose ranges of 1 -100 mg, with 
more than dose -proportional increase especial l
yin area under the concentration time curve 
from time 0 extrapolated to infinity  (AUC inf)from 100 mg to 200 mg in the FIH study . In 
multiple d ose period of the same stud y, both area under the concentration- time curve from 
time 0 to time (AUC ) and Cm
axappeared to increase proportionally  with dose from 10 mg 
to 100 mgQD, with a trend towards greater than proportional increase from 100 mg to 
175mg QD. No direct enzy me inhibition/induction or time-dependent enzy me inhibition has 
been i dentified in
invitro studies. Considering a linear PK at the therapeutic dose range 
being tested in Phase 2 studies (10 –60 mg QD) ,in which single dose PK behavior can
predict multiple dose PK, a single dose study  willbe conducted to evaluate the 
PF-06700841
PK u
nder conditions of renal impairment.
In the preliminary  data of ADME study  B7931014, PF -06802530 (M1) was identified as a 
major circulating metabolite, which was predominantly  eliminated in the urine. The potential 
effects on the cardiovascula r system forboth PF-06700841 and PF -06802530 (M1) were 
evaluated in in vitro human ether -à-go-go-related gene (hERG) potassium channel assay . 
The hERG 50% inhibitory  concentration (IC 50) for PF -06700841 was 33.4 μ M 
(13,000 ng/mL) and the 10% inhibitory  concentration (I C10) is approximately  4 μM 
(1560 ng/mL), which are 49
×and 5.9× , respectively , the predicted human unb ound C maxof 
264 ng/mL at a human dose of 60 mg QD. The IC50for PF -06802530 (M1) was >50 μM 
(>20,300 ng/mL) and the I C10was approximatel y 6.5 μM (2640 ng/mL), which are >77 ×and 
approximately  10× the predicted human unbound C max.Due to the QT prolonga tion concern 
of M1, combined with its primary  elimination pathway of renal e xcretion , understanding of 
M1 exposure change in renal impairme nt is also important in addition to understanding 

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 26parent (PF-06700841) exposure change. Therefore, M1 plasma PK with or without renal 
impairment will be collected and characterized in this study.
PF-06700841 is not highly bound to human plasma proteins, with unbound fraction (f u) of 
0.61 observed in the in vitro protein binding study. Thus, no additional blood samples will be collected in this study for ex vivo protein binding analysis.
 
 
4.3. Justification for Dose
The study will use the PF-06700841 single dose of 30 mg, administered orally. Doses up to 
60 mg of PF-06700841 have been used in longer term efficacy and safety clinical trials. PF-06700841 30 mg is appropriate considering that systemic exposures of PF-06700841 and M1 may be increased in the presence of renal impairment.
Doses of PF-06700841 up to 200 mg single dose and 175 mg QD was generally safe and 
well-tolerated in the Phase 1 clinical study B7931001. There were no deaths, SAE, and serious infection reported in the study. Doses of PF-06700841 up to 60 mg QD was also generally safe and well-tolerated in PsO (B7931001 and B7931004) and AA participants (B7931005). There were no clinical meaningful findings in vital signs, ECG, suicidal behavior or ideation, or potential Hy’s Law cases reported during these studies.
4.4. End of Study Definition
A participant is considered to have completed the study if he/she has completed all phases of 
the study including the last scheduled procedure shown in the Schedule of Activities .
The end of the study is defined as the date of the last scheduled procedure shown in the 
Schedule of Activities for the last participant in the trial.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled.  The 
following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate.  All relevant medical and non-medical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 275.1. Inclusion Criteria
5.1.1. All Participant s
Participant sare eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1.Male or female participants who are between the ages of 18 and 75 years, inclusive, 
at the Screening visit.
Refer to Appendix 4for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2) participant s .
Type of Participant and Disease Characteristics:
2.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, and other study  procedures.
Weight:
3.Body mass ind ex (BMI) of 
≥17.5 to ≤40kg/m2; and a total body  weight >50 kg 
(110 lb). 
Informed Consent:
4. Capable of giving signed informed consent as described in Appendix 1
(Section 10.1) , which includes c ompliance with the requirements and restrictions 
listed in the informed consent document (ICD) and in this protocol.
5.1.2. Additional Inclusion Criteria for 
Healthy Participant s with Normal Renal 
Function (Cohort 2only)
1. N o clinically  relevant abnormalities iden tified by  a detailed medical history , full 
physical examination, including temperature, blood pressure (BP)andpulse rate 
measurement, 12 -lead ECG and clinical laboratory  tests.
2.Normal renal function (eGFR ≥
90mL/min) at 2 Screening visits based on the MDRD
equation . 
3.Demographically  comparable to the group of participant s with impaired renal 
function.
Theeach participant ’sbody  weight within ±15kg of the mean bod y weight of the 
severe renal impairment coh ort(Cohort 1).
The each participant’s age within ±10years of the mean age of the severe renal 
impairment cohort (Cohort 1).

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 28Attempts will be made to ensure that t he male -to-female composition of Cohort 2
iscompar able to th atin the severe renal impairme nt cohort (Cohort 1); cohorts 
cannot be comprised entirely  of any  one gender.
Other demographic characteristic s, such as race and ethnicity , matched as closely  
as possible to the renal impairment cohort (Cohort 1).
5.1.3. Additional Inclusion Criteria for Partic ipant s with 
Impaired Renal Function 
(Cohort 1and Cohorts 3 & 4 [ if applicable ]only)
1. Good general health commensurate with the population with chronic kidney  disease
(renal impairment). “Health” is def ined as no clinically relevant abnormalities 
identifi ed by  a detailed medical history , full phy sical examination, measurement of 
pulse rate and 12 -lead ECG as well as clinical laboratory  tests (except serum 
creatinine and eGFR). Hypertension, diabetes mel litus, hy perparathy roidism, 
ischemic heart disease and other common co -morbidities in this population are 
possible exemptions, as long as, in the opinion of the investigator, the participant is 
medically stable, is on a stable drug regimen, and can abide b ythe meals and dietar y 
restrictions outlined in protocol Section 5.3 .
2.Meet thefollowing e GFR criteria during the screening period based on theMDRD 
equation: 
Severe renal impairment: eGFR <30 mL/min, but not requiring hemodial ysis. 
Moderate renal impairment (Part 2 only ): eGFR ≥ 30 mL /min and 
<60mL/min.
Mild renal impairment (Part 2 only): eGFR between 60 
–89 mL /min.
The eGFR values obtained at the 2 screening visits should not be more than 
25% different (seeSection 4.1 ) .
3.Any form of renal impairment except acute nephritic sy ndrome ( participant s with 
history of previous nephritic sy ndrome but in remission can be included).
4. Stable concomitant drug regimen (as defined in Section 6.5) for the management of 
individual participant ’s medical conditions
; on a case-by-case basis , with input from 
the sponsor, participant s receiving fluctuating concomitant medication/treatment may  
be considered if the underly ing disease is under control.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 295.2. Exclusion Criteria
5.2.1. All Participant s
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Renal transplant recipients .
2.Urinary  incontinenence without catheterization.
3.History  of systemic infectio n requiring hospitalization, parenteral antimicrobial 
therap y, or as otherwise judged clinicall y significant by the investigator within 
6months prior to Day 1.
4.Known history  of pulmonary  embolism or recurrent deep vein thrombosis (DVT).
5.Active acute or ch ronic infection requiring treatment with oral antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1 or 
superficial skin infection within 1 week prior to Day 1.  NOTE: participants may be 
rescr eened after the infection resolves.
6.Have evidence of untreated or inadequatel y treated 
active or late nt infection with 
Mycobacterium tuberculosis (TB) infections as following (see details in Appendix 2 ).
A positive QuantiFERON -TB Gold (QFT- G)In-Tube test performed within the 
3months prior to screening.  If the laboratory  reports the test result as 
indeterminate, the test should be repeated.  If the result of the repeat test is 
indeterminate, a purified protein derivative (PPD ) test ma y be su bstituted for the 
QFT -
GIn-Tube test only with approval from the Pfizer Medical Monitor on a 
case b y case basis;
Note: If a participant has previously  received an adequate course of therapy  for 
either latent (9 months of isoniazid in a loca le where rates o f primary  multi drug 
resistant TB infection are <5% or an acceptable alternative regimen) or active 
(acceptable multi drug regimen) TB infection, neither a QFT -GIn-Tube test nor a 
PPD test need be obtained.
A participant who is being treat ed for latent or active TB infection is not eligible 
for this study .
7.History  (single epi sode) of disseminated herpes zoster or disseminated herpes 
simplex, or a recurrent (more than one episode of) localized, dermatomal herpes 
zoster. 

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 308.Known immunodeficien cy disorder, inc luding positive serology  for human 
immunodeficiency  virus (HIV) at scree ning, or a first -degree relative with a 
hereditary  immunodeficiency .
9.Any present malignancies or history  of malignancies with the exception of adequatel y 
treated or excised non- metast atic basal cell or squamous cell cancer of the skin or 
cervical carcinoma in situ.
10.History  of any  lymphoproliferative disorder such as Epstein Barr Virus (EBV) related 
lymphoproliferative disorder, history  of lymphoma, history  of leukemia, or signs and 
symptoms suggestive of current l ymphatic or l ymphoid disease.
11.Any condition possibly  affecting dr ug absorption (eg, prior bariatric surgery , 
gastrectom y, ileal resection) .
NOTE : participants who have undergone cholecy stectomy  and/or appendect omy 
are eligible for this study so long as the surgery  occurred more than 6 mon ths prior 
to Screening.
12.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active suicidal ideation or behavior or laboratory  abnormality  that ma y 
increase the risk associated with study participation or IPadministration or may  
interfere with the interpretation of study  results and, in the judgment of the 
investigator, would make the participant inappropriate for entry  into this st udy.
Prior/Conco mitant Therapy:
13. P articipant s who have been vaccinated with live or attenuated vaccines within the 
6weeks of dosing, or areto be vaccinated with these vaccines at an y time during 
treatment or within 6 weeks following discontinuation of dosing.
14.Use of con comitant medications that prolong the QT interval within 10 day s prior to 
first dose of IPor 5half-lives (if known), whichever is longer .A list of these 
medications can be found at: http:// www.crediblemeds.org.7
15.Use of prescription or nonprescription drugs and dietary  supplements within 7 day s or 
5half lives (whichever is longer) prior to Day  1.Limited use of nonprescription 
medications that are not believed to affect participant safet y or th e overall result s of 
the study  may  be permitted on a case by  case basis following approval by  the sponsor. 
Herbal supplements and hormone replacement therap y must be discontinued at least 
28days prior to the first dose of investigational product; Depo -Provera®must be 
discontinued at least 6 months prior to dosing of investigational product. 
For participants with renal impairment , stable concomitant medications (including 
herbal supplements)  may be given following 
approval by the sponsor if they are 
considered necessar y for the welfare of the stud y participants (eg ,standard therapy  
for underl ying diseases), are not contraindicated with the IP, and are unlikely  to 
interfere with the PK of the IP. 

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 31Prior/Concurrent Clinical Study Experience:
16.Treatment wi th an investigat ional drug(s) within 30days or 5half-lives (w hichever is 
longe r) preceding the first dose of IP.
Diagnostic Assessments:
17.Infection with hepatitis B or hepatitis C viruses according to protocol -specific testing 
algorithm as described in Appendix 2 (Section 10.2.1). 
18.ANY of the following abnormalities in clinical laboratory  tests at screening, and 
confirmed b y a single repeat, if deemed necessary:
a.Absolute neutrophil count < 1.5 × 109/L (<15 00/mm3);
b.Platelet count <150 × 109/L or <150,000/mm3;
c.Absolute ly mphocy te count of <0.8 ×
109/L (<800/mm3); 
d.Enzy mes aspartate amino transaminase (AST) or alanine amino transaminase 
(ALT) values 
>2× ULN;
e.Total bilirubin >1.5 × ULN; participant s with Gil bert’s syndrome would be 
eligible for th is study  provided the direct bilirubin is ≤ULN;
19.In the opinion of the investigator or Pfizer (or designee), have an y clinically 
significant laboratory  abnormality  that that could affect interpretatio nof study  data or 
the participant ’s participation in th e study .
20.Screening laboratory  tests with abnormal results may  be repeated once to confirm 
abnormal results (with the same screening number); the last value will be used to 
determine eligibility .  
21.Sites may  be permitted to re -screen participant s (with a new screening number) who 
initially  do not meet eligibility  criteria once following agreement with the sponsor.
22.A positive urine drug test, for illicit drugs, at Screening: 
NOTE : repeat urine drug test ing is not permitted in this study .
Renal impairment participants may  be eligible to participate after approval from 
sponsor if their drug screen is positive for a prescribed substance that is not 
expected to interfere with the PK of PF -06700841 .
23.ANY of the following conditions at screening:
a.Screening 12
-lead ECG that demonstrates:

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 32Clinically  significant abnormalities requiring treatment (eg, acute my ocardial 
infarction, serious tach y-or brad y-arrhythmias) or indicating serious 
underlying heart disease ( eg,cardiomy opathy , Wolff -Parkinson–White 
syndrome); 
Confirmed QT interval corrected using Fridericia’s correction factor (QTc F) 
>450 msec for participants with normal renal function and >470 msec for 
participants with impaired renal function.
b.Long QT S yndrom e, a family  history  of Long QT Sy ndrome, or a histor y of 
Torsades de Pointes
. 
Other Exclusions:
24.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  the inves tigator, or 
Pfizer employ ees, including their family  members, directly  involved in the conduct of 
the study . 
25.History  of regular alcohol consumption exceeding 7 drinks/week for females or 
14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine or 12 ounces 
[360 mL] of beer or 1.5 ounces [45 mL] of hard l iquor) within 6 months of Screening.
26. F emale p articipant s of childbearing potential who are unwilling or unable to use 
highl y effective methods of contraception as outlined in Section 5.3.4 for the duration 
of the study  and for at least 28 day s after the administration of investigational 
product , pregnant female participant s, female participants planning to become 
pregnant during the duration of the study  until 28 day safter the administration of 
investigational product, breastfeeding female participant s .
27.Blood donation (excluding plasma donations) of approximately  1pint (500 mL) or 
more within 60days prior to thedose of investigational product .
28.History  of sensitiv ity to heparin or heparin -induced thrombocy topenia, only ifheparin 
is used to flush intravenous catheters used d uring serial blood collections.
29.Unwilling or unable to comply  with the Lifestyle Considerations outlined in
Section
5.3.
5.2.2. Additional Exclusion Criteria fo r Healthy P articipant s with Normal Renal 
Function (Cohort 2, only)
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or 
allergic disease (includin g drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing).

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 332.Evidence or history of clinically significant dermatological condition (eg, contact 
dermatitis , AD, P sO) or visible rash present during ph ysical examination .
3.Screening supine BP >140 mmHg (s ystolic) or > 90mmHg (diastolic), following at 
least 5 minutes of supine rest.  If BP is >140 mmHg (sy stolic) or >90mmHg
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant ’s eligibility .
4.Hemo globin <11.0 g/dL (or 110 g/L).
5.2.3. Additional Exclusion Criteria for 
Participant s with Impaired Renal Function 
(Cohort 1and Cohorts 3 & 4 [if applic able] only)
1. P articipant s requiring hemodialy sis and/or peritoneal dial ysis. 
2.
Participant s with other clinically  significant disease that may  affect the safety  of the 
participant or that may  affect the PKof PF -06700841 (including drug allergies, but 
exclud ing untreated, as ymptomatic, seasonal allergies at time of dosing). Participant s 
with a ny significant hepatic, cardiac, or pulmonary  disease or participant s who are 
clinically  nephrotic.  Hy pertension, diabetes mellitus, hy perparathy roidism, ischemic 
heartdisease, etc. arenot cause for exclusion as long as
, in the opinion of the 
investigat or,the 
participant is medically  stable and any  drugs that are administered 
for these conditions are not expected to interfere with the PKof PF-06700841. 
3.Screening BP≥180 mmHg (sy stolic) or 
≥110 mmHg (diastolic), following at least 
5minutes of supine rest.  If initial BP is ≥180 mmHg (sy stolic) or ≥110 mmHg 
(diastolic), the BP should be repeated two more times and the average of the 3 BP 
values should be used to determine the participant ’s eligibility .
4.Hemoglobin 
<10 g/dL (or 100 g/L) for participants not receiving ery thropoietin ,or 
<9.0 g/dL (or 90 g/L) for participants receiving ery thropoietin.
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Mea ls and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 10 hours prior to the collection of the predose 
PK sample and investigational product administration on Day  1. There will be no
restriction to breakfast on the other day s provi ded other restrictions are followed.
Water is permitted until 1 hour prior to IPadministration. Water may  be consumed 
without restriction beginning 1 hour after dosing.  Nonca ffeinated drinks (except 
grapefruit or grapefruit related citrus fruit juices see below) may  be consumed with 
meals and the evening snack.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 34Lunch will be provided approximately  4 hours after dosing.
Dinner will be provided approximately  9to 10 hours after dosing.
An evening snack may  be permitted.
Participant s will not be allowed to
eat or drink grapefruit or grapefruit- related citrus 
fruits (eg, Seville oranges, pomelos) from 7 days prior to the investigational product 
administration until collection of th e final PK blood sample. 
While confined, the total daily nutritional composition should be approximately  
55% carboh ydrate, 30% fat, and 15% protein.  The daily  caloric intake per p articipant
should not exceed approximately  3200 kcal.
5.3.2. Caffeine, Alcohol, an dTobacco
Participants wil l abstain from caffeine -containing products for 24 hours prior to 
dosing until collection of the final PK sample of each study  period. Participants will 
additionally  abstain from caffeine -containing products at least 2 hours prior to any  
scheduled vital sign and ECG measurements.
Participants will abstain from alcohol for 24 hours prior to admission to the CRU and 
continue abstaining from alcohol until collection of the final PK sample.  Participants 
may undergo an alcohol breath test or blood alcohol test at the discretion of the 
investigator.
Participants will abstain from the use of tobacco -or nicotine -containing products for 
24 hours prior to dosing and during confinement in the CRU.
5.3.3. Activity
Participants will abstain from st renuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests.  Walking at a normal pace will be permitted.
In order to standardize the conditions on PKsampl ing day s, participant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and 
ECG measurements), eating, and drinking beverages other than water during the first 
4
hours after dosing.
5.3.4. Contraception
The investigator or hi s or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant from the permitted list of contraception methods (see Appendix 4 Section 10.4.4) 
and will confirm that the participant has been instructed in its consistent and correct use.  At 
time points indicated in the Schedule of Activities
, the investigator or d esignee wil l inform 
the participant of the need to use highl y effective contraception consistently and correctl y 

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 35and document the conversation and the participant’s affirmation in the participant’s chart 
(participants need to affirm their consistent and cor rect use o f at least 1 of the selected 
methods of contraception).  In addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known or suspected in theparticipa nt or partner .
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  entered in the study . Screen failure data are collected and remain as 
source and are not report ed to the c linical database.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened if prior reason for not meeting the eligibility  criteria has been resolved.  
Rescreening may  only occur with s ponsor ap proval .  Inthe event that the participation of a 
participan t in the study  is delay ed, outdated screening procedures can be repeated.  
Rescreened participants should be assigned the same participant number as for the initial 
screening.  
6. STUDY INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
For the purposes of this protocol, the term invest igational product m ay be used 
synony mously  with study  intervention.
6.1.Study Interventions Administered
For this study , the investigational product isPF-06700841 (provided as 5 and 25 mg tablets) .
PF-06700841 5 and 25 mg tablets will be supplied by  Pfizer to the CRU in bulk along with 
individual dosing containers for unit dosing.
6.1.1. Administration
Investigational products will be administered orally  and according to the conditions 
described in the Schedule of Activities section and Meals and Dietary  Restrictions section of 
this protocol.
Following an overnight fast of at least 10 hours, participants will receive 30 mg 
PF-06700841 tablets (as 1 × 5 mgand 1 × 25 mg ) at approximately  08:00 h ours (plus or 
minus 2 hours) on 
Day 1 with approximately  240 m L ambient temperature w ater. 
Participants will swallow the 2 tablets of PF- 06700841 whole, and will not manipulate or 
chew the investigational product pr ior to swallowing.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 36In order to st andardize the conditions on PKsampling day s, all participant s will be required 
to refrain from ly ing down (except when required for BP ,pulse rate , and ECG 
measurements), eating, and drinking beverages other than water dur ing the first 4 hours after 
PF-06700841 dosing.
6.2.Preparation/Handling/Storage/Accountability
1.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  interventions received and any  
discr epancies are reported and resolved before use of the study  intervention, as 
applicable for temperature -monitored shipments. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer stud y intervention.  All study 
interve ntions must be stored in a secure, environmentally controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized sit e staff.  At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature since previousl y documented for all 
site storage locations upon return t obusiness.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records). All study  
interventions will be accounted for using an investigational product accountability  
form/record.
4.Further guidance and information for the final disposition of unused study  
interventions are provided in the IP manual .
5.Any storage conditions state din the SRSD will be superseded b y the storage 
conditions stated on the product label. 
6.Study  interventions should be stored in their original containers and in accordance
with the label . 
7.Deviations from the storage requirements, including an y actions taken, must be 
documented and reported to Pfizer upon discovery.  The site should actively pursue 
options for returning the study  intervention to the storage conditions described in the 
labeling, as soon as possi ble.  Once an excursion is identified, the stu
dy intervention
must be quarantined and not used until Pfizer provides permission to use the study  
intervention.  I t will not be considered a protocol deviation if Pfizer approves the use 
of the study  intervent ionafter the temperature excursion. Use of t he stud y 
intervention prior to Pfizer approval will be considered a protocol deviation. Specific 
details regarding the definition of an excursion and information the site should report 
for each excursion will be provided to the site in the IP manual .

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 378.Thesponsor or designee will provide guidance on the destruction of unused study  
intervention (eg, at the site).  If destruction is authorized to take place at the 
investigator site, the investigator must ensure t hat the materials are destro yed in 
compliance with applicable environmental regulations, institutional policy , and any  
special instructions provided by  Pfizer, and all destruction must be adequately  
documented.
6.2.1. Preparation and Dispensing
Within this protoc ol, preparation refers to the investigator site activities performed to make 
the investigational product read y for administration or dispensing to the participant by  
qualified staff.  Dispensing is defined as the provision of investigational product, 
conco mitant treatments, and accompany ing informatio nby qualified staff member(s) to a 
healthcare provider, participant in accordance with this protocol.  L ocal health authority  
regulations or investigator site guidelines may use alternative terms for these act ivities.
PF-06700841 tablets will be prepared at the CRU in the individual dosing containers by
2operators, one of whom is an appropriatel y qualified and experienced member of the stud y
staff (eg, ph ysician, nurse, phy sician’s assistan
t, nurse practitione r, pharmacy  
assistant/technician, or pharmacis t). The tablets will be provided in unit dose containers and
labeled in accordance with Pfizer regulations and the clinical site’s labeling requirements.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Investigational Product
The inves t
igator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participant s are enrolled.
The investigator will assign participant numbers to the participant s as they  are screened for 
the study .  All participants enrolled will receive treatment according to the dose/schedule .
6.4. Study Intervention Compliance
Investigational product will be admini stered under the supervision of investigator site 
personnel.  The oral cavity of each particip ant will be examined following dosing to ensure 
the investigational product was taken.
6.5.
Concomitant Therapy
Use of prescription or nonprescription drugs and dietary and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of 
investigational product.  Limited use of nonprescription medications that are not believed to 
affect participant safet y or the overall re sults of the study  may  be permitted on a case-by-case 
basis following approval by  the sponsor .
Acetaminophen/paracetamol may  be used at doses of ≤3 g/day .

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 38Females using hormonal contraceptives or taking hormone replacement therap y may be 
eligible to participate in this study  if they  are willing to discontinue therapy at least 28 days 
prior to the first dose of study  treatment and remain off hormonal therap y for the duration of 
the study .  Depo- Provera®must be discontinued at least 6 months prior to t he first dose of 
study  treatment. Note that another approved method of contraception must then be used 
(Section 10.4.4).
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration.  Concomitant drug and non -drug treatment 
will be c ollected.   All participants will be questioned about concomitant treatment at each 
clinic visit.
Treatments taken within 28 days before the first dose of investigational product will be 
documented as a prior treatment.  Treatments taken after the first do se of investigational 
product will be documented as concomitant treatments.
6.5.1. P articipant s with Healthy Renal Function (Cohort 2 Only)
In general , participants will abstain from all concomitant treatments (prescription or over the 
counter ) as described in the Exclusion Criteria section of the protoc ol, except for the
treatment of AEs .Of note, the following restrictions apply :
Limited use of nonprescription medications that are not believed to affect participant
safet y or the overall results of the study  may  be permitted on a case -by-case basis 
after approval b y the sponsor.
6.5.2. P articipant s with Impaired Renal Function (Cohort 1 and Cohorts 3 & 4 [ if 
applicable ])
Participants are permitted to be on stable doses of background medications i fthey are 
considered necessary  for the welfare of the study  participants (eg,standard therapy  for the 
underly ing disease), are not contraindicated with the investigational product
,and are u nlikely  
to interfere with the PK of the investigational product .Whenever possible , attempts must be 
made to notalter the doses and regimens of the concomitant medic ations after Day 1 and 
until the end of study  on Day 4.
Approved concomitant medications should be administered to renall y impaired 
participants at least 2hours prior to dosing or withheld until 4hours after PF-
06700841 dosing.
6.6. Dose Modification
Dose modifications for PF -06700841 arenot allowed.
6.7.Intervention 
After the End of the Study
No intervention will be provided to study  participants a fterthe end of the study .

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 397.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue 
investigational product.  If investigati onal product is permanentl y discontinued, the 
participant will remain in the study to be evaluated for safety . 
See the Schedule of Activities fordata to be collected at the time of intervention 
discontinuation and follow -up and for an y further evaluations that need to be completed.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request, or may  be 
withdrawn at an y time at the discretion of the investigator for safety , behavioral, compliance, 
or administrative reasons.
At the time of discontinuing from the stu dy, if possible, an earl y discontinuation visit should 
be conducted.  See the Schedule of 
Activities for assessments to be collected at the time of 
study  discontinuation and follow -up and for an y further evaluations that need to be 
completed. 
The early discontinuation visit applies only  to participants who are randomized and then are 
prematur ely withdrawn from the study .  Participants should be questioned regarding their 
reason for withdrawal.  
If a participant wi thdraws from the study , he/she may  request destruction of any  remaining 
samples, but data alread y generated from the samples will c ontinue to be available, and may  
be used to protect the integrity  of existing anal yses.  The investigator must document any  
such requests in the site study  records.
If the participant withdraws from the study  and also withdraws consent (see below) for 
discl
osure of future information, no further evaluations should be performed and no 
additional data should be collected.  The spo nsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
When a participant withdraws from the stu dy because of an SAE, the SAE must be recorded 
on the case report form (CRF ) and reported on the Clinical Trial (CT) SAE Repo rt.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so lo ng as the participant’s safet y was preserved.
Withdrawal of Consent: 
Participant s who request to discontinue receipt of study  treatment will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures.  The onl y 
except ion to this is when a participant specificall y withdraws consent for any further contact 
with him or her or persons previ ously  authorized by  the participant to provide this 

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 40information.  Participants should notify the investigator in writing of the decision to 
withdraw consent from future follow-up, whenever possible.  The withdrawal of consent should be explained in detail in the medical records by the investigator, as to whether the withdrawal is only from further receipt of investigational product or also from study procedures and/or posttreatment study follow-up, and entered on the appropriate CRF page.  In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.
7.3. Lost to Follow-up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:
•The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether or not the participant wishes to and/or should continue in the study;
•Before a participant is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods).  These contact attempts should be documented in the participant’s medical record;
•Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study as a whole is handled as part of Appendix 1 .
8. STUDY ASSESSMENTS AND PROCEDURES
Participants will be screened within 28 days prior to administration of the investigational 
product to confirm that they meet the study population criteria for the study.  The investigator (or an appropriate delegate at the investigator site) must obtain a signed and dated ICD before performing any study-specific procedures.  If the time between screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug shipment), then participants do not require rescreening if the laboratory results obtained prior to first dose administration meet eligibility criteria.
A participant who qualified for this protocol but did not enroll from an earlier group may be 
used in the study without rescreening, provided laboratory results obtained prior to the first dose administration meet eligibility criteria for this study.   
 
 
CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 41Study  proce dures and their timing are summarized in the Schedule of Activities.  Protocol
waivers or exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or a wareness to determine if the participant should continue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the Schedule of 
Activities, is essential and req uired for study  conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria.  The investigator will maintain a screening log to 
record details of all participants screened and to co nfirm elig ibility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumst ances outs ide the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-
being of the participant.  When a protocol-required test cannot be p erformed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
If an intravenous (IV) catheter is utilized for blood sample collections, ECGs and vital sign 
assessments (pulse rate, temperature and BP) should be collected prior to the insertion of the 
catheter.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual participants in this study  is approximate ly 
88mL.  The actual collection times of blood sampling may  change.  Additional blood 
samples may  be taken for safet y assessments at times specified b
y Pfizer, provided the total 
volume taken during the study does not exceed 550 mLduring an yperiod of 60 consecutive 
days.
To prepare for stud y participation, participant s will be instructed on the information in the 
Lifesty le Considerations andConcomitant The rapysections of the protocol.
8.1.Efficacy Assessments
Not applicable.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 428.2.Safety Assessments
Planned time points for all safety  assessments are provided in the Schedul e of Activities.  
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y concerns.
8.2.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, head, ears, ey es, nose, m outh, 
skin, heart and lung examinations, ly mph node s, and gastrointestinal, musculoskeletal, and 
neurological s ystems.
A limited phy sical examination will include, at a minimum, assessments of general 
appearance, the respiratory  and cardiovascular s ystems, and participant -reported sy mptoms.
Physical examin ations may be conducted by a physician, trained ph ysician ’ s assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the Schedule of Activities.  For 
measuring weight, a scale with appropriate range and resolution is used and must be placed 
on a stable, flat surface. Participant s must remove shoes, bulky  layers of clothing, and 
jackets s othat only  light clothing remains.  They  must alsoremove the contents of their 
pockets and remain stil l during measurement of weight.
8.2.2. Vital Signs
Supine BP will be measured with the participant ’s arm supported at the level of the heart, and 
recorded to the nearest mm Hgafter approximately  5minutes of rest.  The same arm 
(preferabl y the dominant arm) will be used throughout the study.  Participant s should be 
instructed not to speak during measurements.
The same properl y sized and calibrated BP cuff will be used to measu re BP each time.  The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery
 for at least 
30seconds.  When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BPand pulse rate will be 
permitted, as necessary, to ensure appropriate colle ction of safety  data.
In some c ases, it may  be appropriate to repeat abnormal vital sign s to rule out measurement 
error s due to e g,improperly  placed BP measurement cuff.
8.2.2.1. Temperature
Temperature will be measured orall y(other body  locations, eg ty mpanic, are acceptable 
provided the sam e method is used and documented throughout the study ).  No eating, 
drinking, or smoking is allowed for 15 minutes prior to the measurement.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 438.2.3. Electrocardiograms
Twelve ( 12)-lead E CGs should be collected at times specified in the Schedule of Activities of 
thisprotocol using an ECG machine that automatically  calculates the heart rate and measures 
PR, QT, and QTc intervals and QRS complex .  All scheduled ECGs should be performed 
after the 
participant has rested quietly forat least 10 minutes in a supine position. 
To ensure safet y of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measuremen ts(
predose on Day  1). Additional ECG monitoring will 
occur if a )a postdose Q Tc interval remains ≥30msec from the baseline and is >450 msec for 
participants with normal renal function (Cohort 2) and >470 msec for participants with 
impaired renal function (Cohort 1, 3, and 4); or b) an absolute QTc value is ≥500 msec for 
any schedu led ECG. If either of these conditions occurs, then 2 additional ECGs will be 
collected approximately  2to 4minutes apart to confirm the original measurement. If the 
QTc values from these repeated ECGs remain above the threshold value, th en a single ECG
must be repeated at least hourly  until QTc values from 2 successive ECGs fall below the 
threshold value that triggered the repeat measurement.
If a) a postdose QTc interval remains ≥
30msec from the baseline and is >450 msec for 
partipants with normal renal function (Cohort 2) and >470 msec for participants with 
impaired renal function (Cohort 1, 3, and 4) ; or b) an absolute QTc value is ≥
500msec for 
any scheduled ECG for greater than 4 hours (or sooner , at the discretion of the investigat or),
or QTc intervals get progressively  longer, the participant should undergo continuous ECG 
monitoring.  A cardiologist should be consulted if QTc intervals do not return to less than the 
criterion listed above after 8 hours of monitoring (or sooner, at the discretion of the 
investigator). 
ECG data will be submitted to a central laboratory for measurement.  The final ECG report 
from the central laboratory should be maintained in the participant’s source documentation 
and be the final interpretation of th e ECG recording.  An y clinically  significant changes from 
the baseline/Day  1 ECG may  potentiall y be AEs ( Appendix 7 ) and should be evaluated 
further, as clinicall y warr anted.  
In some cases, it may  be appropriate to repeat abn ormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordin gs.  If a machine -read QTc 
value is prolonged, as defined a bove, repeat measurements may  not be necessary  if a 
qualified medical provider ’s interpretation determines that the QTc values are in the 
acceptable range.
ECG should be performed before laboratory blood collection.
A paper or digital cop y of the ECG should be filed in the participant ’s chart and must be 
available to the sponsor upon request.  An y clinically  significant changes will be recorded 
and evaluated further, as clinically  warranted.  P articipant s will be discontinued from stud y 
with a confirmed QTc >500 milliseconds or a confirmed QTc change from baseline of 
>60milliseconds.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 44ECG values of potential clinical concern are listed in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the 
Schedule of Activities for the timing and frequency.
The investigator must r eview the laboratory  report, document this review , and record an y 
clinically  relevant changes occurring during the study  in the AE section of the CRF.  
Clinically significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  the investigator to be more severe th an expected for 
the participant ’s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 28 calendar day after t he stud y intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically 
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable b y 
the investigator, the etiology should be identified and the sponsor notified.
All protocol -required laboratory  assessments, as defined in Appendix 2 , must be conducted 
in accordance with the laboratory  manual an d the Schedule of Activities
.
If laboratory  values from non- protocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
Participant s may  undergo random urine drug testing at the discretion of the investigator.  
Drug testing conducted prior to dosing must be ne gative for participant s to receive 
investigational product.
8.2.5. Pregnancy Testing
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL.  Pregnancy  tests will be performed in WOCBP at the times listed in the
Schedule of Activities.  WOCBP must be using be using a permitted contraceptive method to 
be eligible for stud y participation (seeAppendix 4 Section 10.4.3). Following a negative 
pregnancy  test result at screening, appropriate contraception must be commenced and a 
second negative pregnancy  test result will be required at the baseline visit prior the 
participant’s receiving the investigational product.  Pregnancy  tests wi ll also be done 
whenever 1 menstrual cycle is missed during the active treatment period (o r when potential 
pregnancy  is otherwise suspected) and at the end of the study .  Pregnancy  tests may  also be 
repeated if requested b y institutional review boards (I RBs)/ethics committees (ECs) or if 
required b y local regulations. 

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 458.3.Adverse Events and Seriou s Adverse Events
The definitions of an AE and an SAE can be found inAppendix 3 .
AEs will be reported b y the participant (or, when appro priate, b y a caregiver , surrogate, or 
the participant ’s legally  authorized representative).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain re sponsible to pursue 
and obtain adequate information both to determine the outcome and to as sess whether it 
meets the criteria for classification as an SAE or that caused the participant to discontinue the 
study  (see Section 7). 
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the ti me the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedu re and/or receiving investigational product), through and including 
a minimum of 28 calendar days after the last administration of the investigational product (s).
For participants who are screen failures, the active collection period ends when screen failu re 
status is determined.
Medical occurrences that begin before the start of study  intervention but after obtaining 
informed consent will be recorded on the Medical History /Current Medical Conditions 
section of the CRF , not the AE section.
Follow -up by  the 
investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
Investigators are not obligated to activel y seek AE or SAE after conclusion of the study  
participation .  However, if the investigator learns of an y SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify the sponsor.
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Fo rm immediatel y and under no circumstance should this 
exceed 24 hours, as indicated in Appendix 3.  The investigator will submit any  updated SAE 
data to the sponsor within 24 hours of it being available.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 46SAEs occurring in a par ticipant after the active collection period has ended are reported to 
Pfizer Safety if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and ass essing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE r eports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
nonleading ve rbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts.  For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In gener al, follow
-up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant m edications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appe ndix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study interventio n under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.  The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, institutional review boards (IRBs)/ECs , and 
investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regulatory  requirements and sponsor policy  and 
forwarded to investigators as necessary .

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 47An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the investigator’s brochure and will notify  the IRB/EC, if 
appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.3.5.1. Exposure During Pregnancy
Details of all pregnancies in female participants a nd, if indicated, female partners of male 
participants will be collected after the start of study intervention and until 28days after the 
last dose.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 4 .
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
8.3.5.2. Exposure During B reastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding r eport is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is r eported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the 
information does not pertain to a participant enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.3.6. Medication Errors
Medication errors may  result f rom the administration or consumption of the investigational 
product sby the wrong participant, or at the wrong time, or at the wrong dosage strength.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 48Exposures to the investigational product under study  may  occur in clinical trial settings, such 
as medica tion errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the investigational products;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accomp anied by an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are reco rded on an AE page of the 
CRF.
Medication errors should be reporte d to Pfizer Safety  within 24 hours on a CT SAE Report 
Form only when associated with an SAE .
8.4.Treatment of Overdose
For this study , any  dose of PF -06700841 greater than 200 mg within a 24 -hour time period 
will be considered an overdose.
There is no specific antidote for PF -06700841, therefore Pfizer dose not recommend specific 
treatment for an overdose of PF -06700841.
In the event of an overdose, the investigator should:
1.Contact the medical monitor immediately .
2.Closely  monitor the 
participant for an y AEs/SAE s and laboratory abnormalities until 
PF-06700841 can no longer be detected s ystemically  (at least 4days).

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 493. Obtain a blood sample for PK analysis within 4 days from the date of the last dose of 
study intervention if requested by the medical monitor (determined on a case-by-case basis).
4. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
5. Overdose is reportable to Safety only when associated with an SAE.
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant.
8.5. Pharmacokinetics
8.5.1. Plasma for Analysis of PF-06700841 and M1Two (2) blood samples of approximately 3 mL to provide a minimum of 1.2 mL, will be 
collected into appropriately labeled tubes containing potassium ethylenediaminetetraacetic acid (K
2EDTA) for measurement of plasma concentrations of PF-06700841 and M1,
respectively, at times specified in the Schedule of Activities .  The appropriate additive will
be added to the sample collected for M1 PK.  Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by the sponsor.  The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  Collection of samples up to and including 10 hours after IP administration that are obtained within 10% of the nominal time (eg, within 6 minutes of a 60-minute sample) relative to dosing will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and data collection tool (eg, CRF/DCT).  Collection of samples more than10 hours after IP administration that are obtained ≤1 hour away from the nominal time 
relative to dosing will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and data collection tool (eg, CRF/DCT). 
Samples will be used to evaluate the PK of PF-06700841 and M1.  Samples collected for 
analyses of PF-06700841 and/or M1 plasma concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method,  
.
Genetic analyses will not be performed on these plasma samples.  Participant confidentiality 
will be maintained.
Samples collected for measurement of plasma concentrations of PF-06700841 and M1 will 
be analyzed using a validated analytical method in compliance with applicable standard operating procedures (SOPs).
CCI
PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 50The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shipping conditions), including any actions taken, must be documented and reported to the sponsor.  On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.
8.5.2. Urine for Analysis of PF-06700841 and M1
Urine will be collected at the intervals outlined in Schedule of Activities .  Each participant
will empty his/her bladder just prior to dosing.  During the subsequent designated urine collection intervals ([0-24], [24-48], and [48-72] hours post dose), participants will void ALL 
urine produced during the designated collection interval, including a forced void at the end of the collection interval, directly into pre-weighed urine collection container.  Each collection interval should have it’s own collection container(s).  During the entire collection interval, the container(s) should be stored at 4°C. At the end of each urine collection interval, all urine collected will be thoroughly mixed, total weight of urine will be determined first (weigh the empty container first and then weigh the container at the end of the collection)and then the volume of urine will be calculated by assuming specific gravity of urine = 1 and recorded on the CRF. An urine aliquot will be withdrawn for measurement of drug concentrations.  
Additional details for collection, processing and storage of urine for analysis of PF-06700841
and M1 will be added to the laboratory manual and provided to the investigator site prior to the start of the study.
Urine samples will be analyzed using a validated analytical method in compliance with 
Pfizer SOPs, only if it is determined by the study team that there is a need to do so, based on 
review of plasma PK results for PF-06700841 and M1.
8.6. Pharmacodynamics
Pharmacodynamic (PD) parameters are not evaluated in this study.
8.7. Genetics
8.7.1. Specified GeneticsGenetics (specified analyses) are not evaluated in this study.
 
 
 
 
 CCI
PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 51 
 
 
 
  
 
 
 
8.8. Biomarkers
Biomarkers are not evaluated in this study.
8.9. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONSDetailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a statistical analysis plan (SAP), which will be maintained by the sponsor. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
No statistical hypothesis will be tested in this study.
9.2. Sample Size Determination
In Part 1, approximately 8 participants will be enrolled into the normal renal function group 
and the severe renal impairment group to ensure approximately 6 evaluable completers in each group. If Part 2 is conducted, approximately 8 participants will be enrolled to the mild and moderate renal groups to ensure approximately 6 evaluable completers per group. The sample size is based on recommendations from the “FDA Guidance for Industry - Pharmacokinetics in Patients with Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing and Labeling”.
8
Participants who discontinue from the study before completing all assessments may be replaced at the discretion of the investigator and sponsor.CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 529.3.Populations for Analysis
For purposes of analy sis, the following populations are defined:
Population Description
PK Concentration The PK concentration population is defined as all participants 
assigned to investigational product and treated who have at 
least 1 concentration measured .
PK Parameter The PK parameter anal ysis population is defined as all 
participants assigned to investigational product and treated who 
have at least 1 of the PK parameters of primary  interest
measured .
Safety All assigned to investigational product and who take at least 
1dose of investigational product.  
9.4. Statistical Analyses
The SAP will be developed and fina lized before database lock and will describe the 
participant populations to be included in the analy ses, and procedures for accounting for 
missing, unused, and spur ious data. This section is a summary  of the planned statistical 
analyses of the primary  and secondary  endpoints.
Part 1
Analy sis of variance (ANOVA) will be used to compare the natural log transformed AUC inf
and Cmaxfor PF-06700841 and M1 between normal renal function group (Reference) and the 
severe impaired renal function group (Test).  Estimates of the adjusted mean differences 
(Test -Reference) and corresponding 90% confidence intervals (CIs) w ill be obtained from 
the model.  The adjusted mean differences and 90% CI s for the differences w ill be
exponentiated to p rovide estimates of the ratio of the adjusted geometric means 
(Test/Reference) and 90% CIs for the ratios.
Part 2 may  be conducted if either PF -06700841 or M1 AUC infGMR for severe renal 
impairm ent group comp
ared to normal group is≥1.5.
Part 2
ANOVA will be used to compare the natural log transformed AUC infand Cmaxfor 
PF-06700841 and M1 between normal renal function group (Reference) and the moderate 
and mild impaired renal function groups (Test).  Estimates of the adjusted mean differences 
(Test -Reference) and corresponding 90% CIs w ill be obtained from the model.  The adjusted 
mean differences and 90% CIs for the differences w ill be exponentiated to provide estimates 
of the ratio of the adjusted geometric means (Test/Reference) and 90% CIs for the ratios. If 

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 53substantial differences in demographic characteristics between healthy and impaired 
participants are observed, weight and age may be explored as covariates.
Box and whisker plots for individual participant parameters (AUC infand C max) will be
constructed by renal function group and overlaid with geometric means.
For summary statistics and median/mean plots by sampling time, the nominal PK sampling 
time will be used.  For individual participant plots by time, the actual PK sampling time will be used.
If Part 2 is executed and data for normal, mild, moderate and severe impairment groups are
available, additional analysis will be performed to assess relationship between appropriate PK parameters and renal function.
Linear regression will be used to analyze the potential relationship between appropriate PK
parameters (  renal clearance [CL
r], ) and renal function (eGFR). Estimates 
of the slope and, intercept, together with their precision (90% CI), and the coefficient of determination will be obtained from the model.
Plots of PK parameters (  CL
r, ) versus renal function (eGFR) will be 
constructed. A regression line and 90% confidence region for the PK parameters and eGFRwill be included if appropriate. Vertical lines for the renal function group cut-off values will also be presented on the plots. Different symbols will be used to identify participants from different renal function groups.
9.4.1. Efficacy Analyses
An efficacy analysis is not  applicable to this study. 
9.4.2. Safety Analyses
All safety analyses will be performed on the safety population.
AEs, ECGs, BP, pulse rate, and safety laboratory data will be reviewed and summarized on 
an ongoing basis during the study to evaluate the safety of participants.  Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described.  Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and physical examination and neurological examination information, as 
applicable, collected during the course of the study will be considered source data and will 
not be required to be reported, unless otherwise noted.  However, any untoward findings 
identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted.  Demographic data collected at screening will be reported.CCI CCI
CCI CCI
PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 549.4.2.1. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR 
interval, and QRS complex will be summarized by treatment and time.
The number (%) of participants with maximum post-dose QTc values and maximum 
increases from baseline in the following categories will be tabulated by treatment:
Table 3. Safety QTc Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (msec)
Absolute value >450-480 >480-500 >500
Increase from baseline - 30-60 >60
In addition, the number of participants with uncorrected QT values >500 msec will be 
summarized.
 
 
 
9.4.3.1. Pharmacokinetic Analyses
9.4.3.1.1. Analysis PopulationThe PK concentration population will be defined as all participants treated in whom at least 
1 plasma concentration value is reported.
The PK parameter analysis population is defined as all participants dosed who have at least 
1 of the PK parameters of primary interest.
9.4.3.1.2. Derivation of Pharmacokinetic Parameters Prior to Analysis
The plasma PK parameters for PF-06700841 and M1 following single dose administration 
will be derived from the concentration time profiles as detailed in Table 4 .  Actual PK 
sampling times will be used in the derivation of PK parameters.  In the case that actual PK sampling times are not available, nominal PK sampling time will be used in the derivation of PK parameters.CCI
PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 55Table 4. Plasma PK Parameters
Parameter Analyte Definition Method of Determination
 
 
AUC inf*PF-06700841, M1 Area under the plasma 
concentration-time profile from time 0 extrapolated to infinite timeAUC
last+( C last*/k el), Where C last* is 
the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis.
AUC 72 PF-06700841, M1 Area under the plasma 
concentration-time profile from 
time 0 to 72 hours post doseLinear/Log trapezoidal method.
Cmax PF-06700841, M1 Maximum plasma concentrat ion Observed directl y from data.
 
 
 
 
 
 
* As data permit.
If urine samples need to be analyzed (See Section 8.5.2 ), the following urine PK parameters 
(Table 5) will be calculated for PF-06700841 and M1 (as data permit):
Table 5. Urine PK Parameters
Parameter Analyte Definition Method of Determination
Ae72 PF-06700841, M1 Total amount of unchanged drug 
excreted in the urine over 72 hoursSum of amount excreted for each 
collection period.
Ae72% PF-06700841, M1 Total amount of unchanged drug 
excreted in the urine over 72 hours, expressed as percent of dose100×(Ae
72/Dose)
CL r PF-06700841, M1 Renal clearance Ae 72/AUC 72
Urine PK parameters will be analyzed and summarized using descriptive statistics.
9.5. Interim Analyses
No formal interim analysis will be conducted for this study. As this is an open-label
study, the sponsor may conduct unblinded reviews of the data during the course of the study for the purpose of safety assessment.CCI
CCI
C
CI
CCI
CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 569.5.1. Data Monitor ing Commi ttee 
This study  will not use a data monitoring committee (DMC) .

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 5710. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS ) International Ethical Guidelines;
Applicable International Council for Harmonisation (I CH) Good Clinical Practice 
(GCP) guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CD, IB, and other 
relevant docume nts (eg, 
adve rtisements) must be reviewed and approved by  the sponsor and submitted to an I RB/EC 
by the investigator and reviewed and approved b y the IRB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before i mplementa tionof 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IR B/EC annually or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures;
Providing oversight of the conduct of the s tudy at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), I CH guidelines, the I RB/EC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations.
10.1.1.1. Repor ting of Safety Issues an d Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that mi ght influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately.  In addition, the investigator will inform 
Pfizer immediately  of any  urgent safet y measures taken b y the investigat or to protect t he 
study  participants against any  immediate hazard, and of any  serious breaches of this protocol 
or of ICH GCP that the investigator becomes aware of.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 5810.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with suff icient, accurat e financi al 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities.  I nvestigators 
are responsible for providing information on financial inte rests dur ing the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study .
Participants must be informed that their participation is voluntary .  Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, Health Insurance Portabilit y and Accountability  Act
(HIPAA) requirements, where applicable, and the I RB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the stu dy, and possibl e risks 
associated with participation, including the risks associated with the processing of the 
participant’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  the 
sponsor in accordanc e with local da ta protec tionlaw.  The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appoint ed by  the spons or, by  
appropriate IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw conse nt for th e 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained.  
The au thorized person obtainin g the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .
A cop y of the ICD(s) must be provided to the participant.
Participant s who are rescr eened are required to sign a new ICD.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 5910.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participan ts’ personal da ta will be stored at the study  site in encry pted electronic form and 
will be password protected to ensure that onl y authorized study  staff have access.  The study  
site will implement appropriate technical and organizational measures to ensur e that the 
personal data can be recovered in the event of disaster.  In the event of a potential personal 
data breach, the stud y site shall be responsible for determining whether a personal data 
breach has in fact occurred and, if so, providing breach noti fications as re
quired by law.
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code.  
Any participant records or data sets that are transferred to the sponsor will contain the 
numerical code; participant names will not be transferred.  All other identifiable data 
transferred to the sponsor will be identified by  this single, participant -specific code.  The 
study  site will maintain a con fidential list of partic ipants who participated in the study , 
linking each participant’s numerical code to his or her actual identity .  In case of data 
transfer, the sponsor will protect the confidentiality of participants’ personal data consistent 
with th e clinical stud y agreeme nt and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on 
www.clinicaltrials.gov (ClinicalTrials.gov), the European Cli nical Tri als 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.  I n addition, Pfizer reports study  results outside of the 
requirements of local laws/regulations pursua nt to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinic al trial US Basic Results on www.clinicaltrials.gov for Pfizer -sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
product, regardless of the geographical location in which the study is cond ucted.  US Basi c 
Results are generall y submitted for posting within 1 year of the primary completion date 
(PCD) for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final p articipant was examined or received an intervention 
for the purposes of final collection of data for the primary  outcome, whether the clinical 
study  concluded according to the prespecified protocol or was terminated.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 60EudraCT
Pfizer posts European Union (EU) Basic Results on Eudra CT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric p opulations.
www.pfizer.com
Pfizer posts public disclosure s ynopses (clinical study  report [ CSR ]synopses in which any  
data that could be used to identify  individual participants have been removed ) on 
www.pfizer.com for Pfizer- sponsored inter ventional studi es at the same time the US Basic 
Results document is posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the Euro pean Medi cines Agency  (EMA) website.  Clinical data, under Phase 1 of this 
policy , includes clinical overviews, clinical summaries, CSRs, and appendices containing the 
protocol and protocol amendments, sample CRFs, and statistical methods.  Clinical data, 
under Pha se 2 of this policy , includes the publishing of individual participant data.  Policy  
0070 applies to new marketing authorization applications submitted via the centralized 
procedure since 01 January 2015 and applications for line ex tensions and fo
r new indications 
submitted via the centralized procedure since 01 July  2015.
Data Sharing
Pfizer provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to th e scientific un derstanding of the 
disease, target, or compound class. Pfizer will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  C SRs will have personall yidentifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a biostatistician.   Data will not 
be provid
ed to applic ants with si gnificant conflicts of interest, including individuals 
requesting access for commercial /competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF u nless 
transm itted to the sponsor or designee electronically  (eg, laboratory  data).  The investigator is 
responsible for verify ing that data entries are accurate and c orrect by  physically  or 
electronically  signing the CRF.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 61The investigator must maintain acc urate docume ntation (sou rce data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic form and are password protected to prevent access b y unauthorized t hird parties.
The invest igator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.  This 
verification may  also occur after study  completion.  I t is important tha t the invest igator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspectio ns and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk- based initiatives in opera tions and quality  
such a s risk management and mitigation strategies and anal ytical risk- based monitoring), 
methods, responsibi lities, and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monito ring), are provided in t he 
monitoring plan.
The sponsor or designee is responsible for the data management of this study , incl uding 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
intothe CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently
 approved protocol and any other study  
agreeme nts, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICDs , pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local re gulations or
institution al policies require a longer retention period.  No records may be destroyed during 
the retention perio d without the written approval of the sponsor.  No records may  be 
transferred to another location or party without written notific ation to the sponsor.  T he 
investigator must ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irre vocabl y dele ted from all systems.
The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prep are the inve stigator sit e for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the study data and the partici pant’s medical records.  The investigator will promptly  
provide copies of the inspection findings to the sponsor or its agent.  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or i ts 
agents wi th an opport unity  to review and comment on responses to any  such findings.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 6210.1.7. Source Documents
Source documents provi de evidence for the existence of the participant and substantiate the 
integrit y of the data collected.  Source documents are filed at the inve stigator sit e.
Data reported on the CRF or entered in the electronic CRF (eCRF) that are transcribed from 
source d ocuments must be consistent with the source documents or the discrepancies must be 
explained.  The investigator may  need to request previous m edical recor ds or transfer 
records, depending on the study .  Also, current medical records must be available.
Definition of what constitutes source data can be found in Data Handling Plan .
10.1.8. Study and Site Closure
The sponsor designee reserves th e right to c lose the stu dy site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor.  Stud y sites will be closed upon 
study  completion.  A study  site is considered closed when all required documents and study  
supplies ha ve been coll ected and a study -site closure visit has been performed.
The investigator may  initiate study -site closure at any  timeupon notification to the contract 
research organization (CRO) if requested to do so by  the responsible IRB/EC or if such 
termi nation is re quired to pr otect the health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor m ay include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or loca l health authorities, the sponsor ’s procedures, or GCP guidelines;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development.
Study  termination is also provided for in the clinical study agreement .  If there is an y confl ict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overa ll study  results or 1 y ear after end of the study  (or 
study  termination), whichever comes first. 
The invest igator agrees to refer to the primary  publication in any  subsequent publications 
such as secondary  manuscripts, and submits all manuscri pts or abstr acts to the sponsor 
30days before submission.  This allows the sponsor to protect proprietary  information a nd to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosu re, excep
t for any  study -or Pfizer -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 63For all publications relating to the stud y, the investigator will compl y with recognized ethic al 
standa rds concerning publications and authorship, including those established by  the 
International Committee of Medic al Journal Editors.
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites.  In accordance w ith standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.  I n this case, a coordinating investigator will be designated by  mutual
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agre ement, th e publication p olicy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor ’s appropriately  qualified medical personnel for the 
study  is documented in the study  contact list located in
the stud y team on demand (SToD) 
system. 
To facilitate access to appropriatel y qualified medical personnel on s tudy-related medical 
questions or problems, participants are provided with a contact card.  The contact card 
contains, at a minimum, protocol an d investi gational produc t identifiers, participant numbers, 
contact information for the investigator site, and c ontact details for a contact center in the 
event that the investigator site staff cannot be reached to provide advice on a medical 
question or p roblem or iginating from another healthcare professional not involved in the 
participant’s participation in the s tudy.  The contact number can also be used by  investigator 
staff if they  are seeking advice on medical questions or problems; however, it should be used 
only in the eve nt that the established communication pathway s between the investigator site 
and the study  team are not available.  It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigato r site and the study  team for 
advice on medical questions or problems that may arise during the stud y.  For site s other than 
a Pfizer CRU, the contact number is not intended for use b y the participant directly, and if a 
participant calls that number, he or she will be directed ba ck to the investigator site.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 6410.2. Appendix 2: Clinical Laboratory Tests
The following safet ylaboratory  tests ( Table 6) will be performed at times defined in the 
Schedu
le of Act ivities section of this protocol.  Additional laboratory  results may be reported 
on these samples as a result of the method of analysis or the t ype of anal yzer used b y the 
clinical laboratory ;or as derived from calculated values.  These addition al tests would not 
requi re additio nal collection of blood.  Unscheduled clinical laboratory  measurements may  
be obtained at an
y time during the stud y to assess any perceived safet y concerns.
Table 6. Protocol -Required Safety Laborator y Assessm ents
Hem atolog y Chemistr y Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs 
and %)
Eosinophils (Abs and %)
Monocytes (Abs and %)
Basophils (Abs and %)
Lymphocytes (Abs and 
%)BUN/urea and 
creati ninea
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Albumin
Total protein
Uric acid
Creatine kinase
Additional Assessments 
for Hy’s Law:
AST ,ALT  (repeat)
Total bil irubin (repeat)
Albumin (repeat)
Alkaline phosphatase 
(repeat)
Creatine kinase (repeat)
Direct bilirubin
Indirect bilirubin
GGT
PT/INR
Total bile acidspH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esteras e
Urobili nogen
Urine bil irubin
MicroscopybFSHc
Pregnancy test 
(β-hCG)d
eGFR
HBsAge
HBcAbe
HbsAbe
HCVAbe
HIVe
QuantiFERON-TB 
Gold Test or PPDe
Breath or urine alcoh ol 
testf
Urine drug screeningg
Urine myoglobinh
Abbreviations: Abs = absolute; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
β-hCG =beta-human chorionic gonadotropin; BUN = blood urea nitrogen; CO 2 = carbon dioxide; 
eGFR = estimated glomerular filtration rate; FSH = follicle -stimulating hormone; GGT =gamma -glutamyl 
transferase; HBcAb = hepatitis B core antibody; H BsAb = h epati tis B surface antibody; H BsAg =hepatitis B 
surface antigen; hCG = human chorionic gonadotropin ;HCVAb = h epatitis C antibody; HIV = human 
immunodeficiency virus; INR = international normalized ration; MCH = mean corpuscular hemoglobin; 
MCHC =mean corpusc ular hemoglobin concentration; MCV = m ean corpuscular volume; PT =prothrombin
time; qual = qualitative; RBC = red blood cell; S1= Screening Visit 1 ; 
S2= Screening Visit 2; THC =tetrahydrocannabinol; ULN = upper limit of normal ;WBC =white blood cell. 

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 65a.Only serum creatinine on Screening Day 2 (S2) for eGFR assessment.
b.Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
c.At Screening (S1) f or confirmation of postmenopausal status only.
d.Urine or Serum -hCG for female participants of childbearing potential according to Schedule of 
Activities .
e.Com plete at screening (S1).  Previous testing for QuantiFERON-TB Gold Test w ill be accepted if 
completed within 3 months prior to screeni ng.  Otherwise should be completed at screening and r esults 
available prior to Day -1.If QFT -G test cannot be performed, or if results cannot be determined positive 
or negative, participant s may be screened using PPD Tuberculin Test (Mantoux method) with approval 
of medical monitor .HBsAb will be performed as reflex testing for any participant who is HBsAg 
negative but HBcAb positive.   HCV RNA will be performed as reflex testing for any participant who is 
HCV Ab positive.
f.Com plete at screening (S1) and D ay -1.
g.At Screening (S1) 
and Day -1. The minimum requirement for drug screening includes cocaine, 
tetrahydrocannabinol (THC), opiates/opioids, benzodiazepines, and amphetamines (others are site and 
study specific).
h.Reflex testing for creatine kinase >10 ×ULN .
Investigators must document th eir review of each laboratory  safet y report.
Participants may  undergo random urine drug testing at the discretion of the investigator.  
Drug testing prior to dosing must be negative for participants to receive investiga tional 
product .
10.2.1. Hepatitis B and C Testing Algorithm and Full Eligibility Criteria
All participants will undergo screening for hepatitis B and C for eligibility .
At screening, HBsAg and HBcAb will be tested:
a.If both tests are negative, the participant is el igible for study  inclusion .
b.If HBsAg is positive, the participant must be excluded from participation in the study .
c.If HBsAg is negative and HBcAb is positive, HBsAb reflex testing is required:
iIf HBsAb is negative, the participant must be excluded from p articipation in the 
study ;
iiIf HBsAb is positive, the participant is eligible for study  inclusion. 
At screening ,HCVAb will be tested:
a.Participants who are HCVAb positive will be reflex -tested for HCV RNA.
b. P articipants who are p ositive for HCVAb and HC V RNA will not be eligible for this 
study .

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 6610.2.2. Tuberculosis Testing
During the Screening period, it must be determined and documented that a participant does 
not have evidence of untreated or inadequatel y treated active or latent infection with 
Mycobacterium tuberculosis (TB) per exclusion criterion # 6(Section 5.2.1 ).  The results of 
TB screening conducted within 3 months prior to screening or during the Screening period 
must be documented in study  records prior to Baseline.
QFT -GIn-Tube test is the preferred testing method.  If the laboratory reports that the QFT -G 
test results are indeterminate, the test should be repeated. If the result of the repeat test is 
indeterminate, then participa ntsmay bescreened using the PPD Tuberculin Skin Test 
(Mantoux method) with approval of the Pfizer Medical Monitor.
10.2.2.1. Purified Protein Derivative Test
If the QFT- G In-Tube test cannot be performed or if the QFT -G results are indeterminate , 
then participants may be screened using the PPD Tuberculin Test (Mantoux method) if 
approved b y the Pfizer medical monitor .
Participants must have the PPD test administered and evaluated b y a health care professional 
48 to 72 hours later in order to be eligible for the st udy.  The test should be performed 
according to local standards (eg,induration of <5 mmbeing a negative result ).

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 6710.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an
y unfavorable and uni ntended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemis try, or urinalysis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator ( ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y interventio n administratio n even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concom itant medication.  Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent.  Such overdoses should be reported regardless of 
sequelae.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 68Events NOT Meeting the A E Definition
Anyclinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/dis order being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads t o the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condit ion(s) present 
or detected at the start ofthe study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospitalization for signs/symptoms of the disease un der study , death 
due to progression of d isease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a. Results in death .
b. Is life -threatening.
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event.  I t does not refer to an event that 
hypothetically  might have caused death if it were more severe.
c. Requires inpatient hospitalization or prolongation of existing hospitalization .
In general, hospitalization signifies that the part icipant has been detained (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting.  Complications that occur duri nghospitalization are AEs.  If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious.  When in doubt as to whether “hospitalization” occurred or was necessary , the AE 
should be considered serious.
Hospitaliza ti
on for elective treatment of a preexisting condition that did not worsen from 
baseline is not considered an AE.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 69d. Results in persistent disability/incapacity .
The term disability means a substantial disruption of a person’s ability  to conduct 
normal li fefunctions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e. Is a congenital anomaly/birth defect.
f. Other situations:
Medical or scientific judgment should be exercised in deciding wheth er SAE 
reporting is appropriate in other situati ons such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but 
may jeopardize the participant or may  require medical or surgical intervention to 
pr
event one of the other outcomes listed in the above definition.  These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not re sult in hospitalization, or development of drug 
dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF and 
for repo rting serious adverse events on the CT SAE Report Form to Pfizer Safety .  These 
requirements are delineated for 3 t ypes of events: (1) SAEs; (2) nonserious AEs; and 
(3)exposure to the investigational product under study  during pregnancy  or breastfeeding, 
and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be rec orded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 70Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of
Awareness
SAE All All
Nonserious AE All None
Exposure to the 
investigational product 
under study  during 
pregnancy  or 
breastfeeding, and 
occupational exposureNone All (and exposure during 
pregnancy  [EDP] 
supplemental form for 
EDP)  
When an AE/SAE occ urs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnost ic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety  in lieu of completion of the CT SAE Report 
Form/AE/SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety.  In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagno sis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event tha t causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities.  An AE that is assessed 
as severe should not be confused with an SAE.  Severe is a category  utilized for 
rating t he inte nsity of an event; and both AEs and SAEs can be assessed as severe.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 71An event is defined as “serious” when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, r ather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal re lationship o f the event to stud y intervention 
administration will be considered and investigated.
The investigator will also consult the IBand/or product information, for marketed 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in whic h an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor.  However, it is
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opinion of causality  in light of follow -up 
information and se ndan SAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when det ermining regulatory  
reporting requirements.
If the investigator does not know whether or not the investigational product caused 
theevent, then the event will be handled as “related to investigational product” for 
reporting purposes, as defined by  the spon sor.  In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator must 
record t his causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE R eport Form and in accordance 
with the SAE reporting requirements.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 72Follow -up of AEs and SAEs
The investigator is obligated to p erform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested b y the 
sponsor to elucidate the nature and/or causalit y of the AE or SAE as fully as 
possible.  This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare professionals.
If a participant dies during participation in the study  or during a recognized 
follow -
up period, the investigator will provide Pfizer Safet y with a copy of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Report ing of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary  mechanism for re porting an SAE to Pfizer Safety  will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic d ata collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data colle ction tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to Pfizer Safety  by telephone.
SAE Reporting to Pfizer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the facsimi le is not working, notification by  telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  overnight mail or 

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 73courier service.
Initial not ification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Re port Form pages within the designated reporting 
time frames.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 7410.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Partici pant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28 daysafter the last dose of stud y intervention, which
corresponds to the time needed to eliminate stud y intervention(s):
Refrain from donating sp erm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) a nd
agree to remain abstinent. 
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person.
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is e ligible to participate if sh e is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3 ).
OR
Is a WOCBP and using a contraceptive method tha t is highly  effective (with a failure 
rate of <1% per year), preferabl y with low user dependency, as described below 
(Section 10.4.4) during the intervention period and for at least 28 day safter the last 
dose of study  interventi on,which corresponds to the time needed to eliminate an y 
study  intervention(s).
A WOCBP agrees not to donate eggs (ova, oocy
tes) for the purpose of reproduction 
during this period.  The investigator should evaluate the effectiveness of th e 
contraceptive method in relationship to the first dose of study  intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a wom an with an earl y undetec ted 
pregnancy .

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 7510.4.3. Woma n of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cann ot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenarchal.
2.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Docume nted bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examinatio n, or 
medical history  interview.   The method of documentation should be record ed in the 
participant’s medical record for the stud y.
3.Postmenopausal female.
A postmenopausal state is defined as age 60 years or older or no menses for 
12months without an alte rnative medical cause. 
A high follicle -stimulating hormone (F SH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormone replacement therap y (HRT).
Females on HRT and whose menop ausal status is in doubt will be required to 
use one of the no nestrogen hormon al 
highl y effective contraception methods 
if they  wish to continue their HRT during the study .  Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal statu s before study  
enrollment.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 7610.4.4. Contraception Methods
Highly Effect ive Methods That Have Low User Dependency 
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device (IUD).
3.Intrauterine hormone -releasing s ystem (IUS).
4.Bilateral tubal occlusion.
5.Vasectomized partner.
Vasectomized partne r is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed.  If not, an additional highl y effective method of contraception 
should be used.  The spermatogenesis cycle is approximately  90 day s.
Highly Effective Methods That Are User Dependent
1.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation.
Oral;
Intravaginal;
Transdermal;
Injectable .
2.Progestogen -only hormone contraception associated with inhibition of ovulation.
Oral;
Injectable .
3.Sexual abstinence.
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire p eriod of risk a ssociated 
with the study  intervention.  The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 77Collection of Pregnancy Information
For bot h unapproved/unlicensed products and for marketed products, an EDP occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female be come s or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a n urse re ports that she 
is pregnant 
and has been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during hi s partner’s pre gnan cy.
If a participant or participant’s partner becomes or is found to be pregnant during the 
participant’s treatment with the investigational product, the investigator must report this 
information to Pfizer Safety  on the CT SAE Report Form and an EDP supple mental form, 
regardless of whether an SAE has occurred.   In addition, the investigator must submit 
information regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a 
participant reports that she is pregnan t and h as been exposed to a cytotoxic product by  
inhalation or spillage) to Pfizer Safety
 using the EDP supplemental form.  This must be done 
irrespective of whether an AE has occurred and within 24 hours of awareness of the 
exposure.  The information subm itted should include t he anticipated date of delivery  (see 
below for information related to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The i nvestig ator will follo w the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -
up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can b e asses sed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure tes t findings are conc lusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital a nomal y [in a 
live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SA Es 
follows: 
Spontaneo us abortion includes miscarriage and missed abortion;

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 78Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assess es the infant death as related or possibly  related to 
exposure to the investigational product. 
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -
up of birth outcomes will be handled on a case- by-case basis (eg, foll ow-up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigat or must document in the source documents that 
the participant was giv en the Pregnant Partner Release of Information Form to provide to his 
partner.

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 8010.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments 
Pote ntial Cases of Drug -Induced Liver Injury
Humans exposed to a dr ug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In som e participants, transaminase elevations are a harbinger of a 
more serious pote ntial outcome.  These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as drug -induced 
liver injury  (DILI) .  Participants who experience a transaminase elevation above 3 ×ULN 
should be monitored more frequently  to determine if they  are an “adaptor” or are 
“susceptible.”
In the majority  of DILI cases, elevations in AST and/or A LTprecede total bilirubin (TBili) 
elevations (>2 ×ULN) by  several day s or weeks.  The increase in TBili typic allyoccurs 
while AST/AL T is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be 
elevated within the same laboratory  sample).  In rare instances, by  the time T Bili elevations 
are detected, AST/ALT values might have decreas ed.  This occur rence is still regarded as a 
potential DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potent ial DILI (assessed per Hy ’s law 
criteria) cases and should alwa ys be considere d important medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions.  Pa rticipants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili b aseline values within the normal range who 
subsequently  present with AST OR AL T values >3 × ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2× ULN or not available.
For participants with baseline AST ORALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values > 2times the baselin e values AND >3 × ULN; or >8 × ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at le ast 1 × ULN orif the value reaches 
>3×ULN (whichever is smal ler).

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 81Rises in AST/ ALT and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The participant shoul d return to t he investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include lab oratory  tests, detailed history , and physical assessment.
In ad dition to repea tingmeasurements of AST and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time (PT)/inte rnational 
norma lized ratio (INR) , total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous an alyses at the t ime 
of the recogn ized 
initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over -the-count er medications) , recreational dr ug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusi on, history  of liver or allergic disease, and 
potential occupat ional exposure to c hemicals, sho uld be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum sample for aceta minophen drug and/or protein adduct levels may  be warranted. 
All cases demons
trated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason f or the liver function test ( LFT)abnormalities has y et been found.  Such 
poten tialDILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of the investigations performed to determine etiology of the LFT 
abnormalit ies.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 8210.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as Adverse Events (AEs)
Marked sinus brady cardia (rate<40beats per minute [bpm]) lasting minutes.
New PR interval prolongation >280 millisecond (msec ).
New prolongation of QTcF to >480 msec (absolute) or by60msec from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular respons erate:
ie, ra te <120 bpm.
New -onset ty peI second -degree (Wenckebach) atrioventricular ( AV) block of 
>30seconds’ duration.
Frequent premature ventricular complexes (PVCs), triplets, or short intervals 
(<30 seconds) of consecutive ven tricular complexes.
ECG Findings T hat May Qualify as Serious Adverse Events (SAEs)
QTcF prolongation >500 msec.
New ST- T changes suggestive of my ocardial ischemia.
New -onset left bundle branch block (QRS >120 ms ec).
New -onset right bundle branch block (QRS >120 msec).
Symptomati c brad ycardia. 
Asystole:
In awake, s ymptom -free participants in sinus rhy thm, with documented periods 
of as ystole  3.0 seconds or an y escape rate <40 bpm, or with an escape rhythm 
that is below the AV node. 
In awake, s ymptom -free participants with a trialfibrillation and brad ycardia 
with 1 or more pauses of at least 5 seconds or longer. 
Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular tach ycardia (rate >120 bpm) (“sustained” = sh ort 
duration wi th relevant s ymptoms or lasting >1 minute).
Ventricular rh ythms >30 seconds’ duration, including idioventricular rhy thm (rate 
<40 bpm), accelerated idioventricular rh ythm (40< x <100), and 

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 83monomorphic/poly morphic ventricular tachy cardia >100 bpm (such as t orsades de 
pointes).
Type II second -degree (Mobitz II) AV block.
Complete (third- degree) heart block.
ECG Findings That Qualify as Serious Adverse Events
Change in pattern sugg estive of new myocardial infarction. 
Sustained ventricular tac hyarrhythmias ( >30 seconds’ duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular re sponse requiring cardioversion.
Ventricular fibri llation/flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the inves tigator an d Pfizer study team, and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 8410.8. Appendix 8: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
AA alopecia areata
Abs absolute
AD atopic dermatitis
ADME Absorption, Distribution, Metabolism and Elimination
AE adverse event
ALT alanine aminotransferase
ANOVA analysis of variance
AST aspartate aminot ransferase
AUC area under the curve
AUC 24 area under the concentration-time curve from time 0 to 24 hours
AUC inf area under the concentration-time curve from time 0 to infinit y
AUC last area under the concentration-time curve from 0 to time of last 
measurable concentration
AUC τ area under the concentration-time curve from time 0 to time τ
AV atrioventricular
β-hCG beta-human chorionic gonadotropin
BMI body mass index
BP blood pressure
bpm beats per minute
BSA body surface area
BUN blood urea nitrogen
CD Crohn’s disease
CFR Code of Federal Regulations
C-G Cockcroft Gault
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD Chronic Kidney Disease
CL cr creatinine clearance
CL r renal clearance
Clast last quantifiable concentration
Cmax maximum plasma concentration
CO 2 carbon dioxide (bicarbonate)
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR clinical study reportCCI
CCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 85Abbreviation Term
CT clinical trial
CYP450 cytochrome P450
DC discontinuation
DCT data collection tool
DILI drug-induced liver injury
DMC data monitoring committee
DNA deox yribonucleic acid
DVT deep vein thrombosis
EBV Epstein Barr Vi rus
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administrati on
FIH first-in-human
fm fraction metabolized
FSH follicle -stimulating hormone
fu unbound fraction
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma -glutamy l transferase
GMR geometric mean ratio 
HBcAb hepatitis B core antibod y
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
hCG human chorionic gonadotropin
HCV hepatitis C
HCVAb hepatitis C antibody
HDL lipoprotein
hERG human ether -à-go-go-related gene
HIPAA Health Insurance Po rtability  and Accountabi lity Act
HIV human immunodeficiency virus
HRT hormone replacement therap y
HS hidradenitis suppurativa
IB investigator’s brochure
IBD inflammatory  bowel disease
IC10 10% inhibitory  concentration
IC50 50% inhibitory  concentrati on
ICD informed consent document

PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 86Abbreviation Term
ICH International Council for Harmonisation
IFN interferon
IL interleukin
IND investigational new drug 
INR international normalized ratio
IRB institutional review board
IUD intrauterine device
IUS intrauterine hor mone releasing s ystem
IV intravenous
JAK Janus kinase
K2EDTA ethylenediaminetetraacetic acid
KDOQI Kidney  Disease Outcomes Quality  Initiative
LDL lowdensity  lipoprotein
LFT liver function test
MAD multiple ascending dose
MATE multidrug toxin extru sion protein
MCH mean c orpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDRD Modification of Diet in Renal Disease
msec millisecond
N/A not applicable
NOAEL no-observed -adverse -effect level
OCT2 organ ic cation transport 2
P-gp p-glycoprotein
PASI Psoriasis Area and Severity  Index
PCD primary  completion date
PD pharmacod ynamic(s)
PK pharmacokinetic(s)
PPD purified protein derivative
PsA psoriatic arthritis
PsO psoriasis
PT prothrombin time
PVC premature ventricular contraction/complex
QD once dail y
QTc corrected QT
QTcF QT interval corrected using Fridericia’s correction factor
QFT -G QuantiFERON-TB Gold
qual qualitative
QW once a week
RBC red blood cell
RNA ribonucleic acid
SAD single ascending dose

PF-06700841
Protocol B7931048Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 87Abbreviation Term
SAE serious adverse event
SAP statistical analysis plan
SCr serum creatinine
SLE systemic lupus erythematosus
SoA schedule of activities
SOC system organ class
SOP standard operating procedure
SRSD single reference safety document
SToD study team on demand
SUSAR suspected unexpected serious adverse reaction
t½ terminal elimination half-life
TB tuberculosis
TEAEs treatment emergent adverse events
TBili total bilirubin
Th17 T help 17
THC tetrahydrocannabinol
Tmax time to maximum concentration
TYK2 tyrosine kinase 2
UC ulcerative colitis
ULN upper limit of normal
US United States
WBC white blood cell
WOCBP woman of childbearing potentialCCI
PF-06700841
Protocol B7931048
Final Protocol, 20 November 2019
PFIZER CONFIDENTIAL
Page 8811.REFERENCES
1. National Kidney  Foundation. (2002) K/DOQI Clinical practice guidelines for chronic 
kidney  disease: Evaluation, classification, and stratification. Am J Kidney  Dis. 39(2 
Suppl 1):S1-266.
2. Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients 
with Decreas ed Renal Function . EMA Committee for Medicinal Products or Human use.  
20 Feb 2014.
3. Nalbandian A, Crispin JC, Tsokos GC. I nterleukin -17 and s ystemic lupus 
erythematos us: current concepts. Clin Exp I mmunol 2009; 157(2):209 -
15.
4. Ardoin ST and Pisetsky  DS.  De velopments in the scientific understanding of lupus. 
Arthritis Res Ther 2008; 10(5):218.
5. Schwatzman- Morris J and Putterman C. Gender differences in the pathogenesis a nd 
outcome of lupus and of lupus nephritis. Clin Dev I mmunol 2012; 2012:1 -
9.
6. FDA. Draft Gu idance for I ndustry : Pharmacokinetics in Patients with I mpaired Renal 
Function — Study  Design, Data Anal ysis, and Impact on Dosing and Labeling; March 
2010. Accessed 07 December 2017. 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Gui
dances/UCM204959.pdf .
7. Woosley  RL, Heise CW, Gallo T, Tate J, Woosley  D and Romero KA, 
www. Credible Meds.org , QTdrugs L ist, (Accessed on 15 Apr 2019), AZCERT, I nc. 
1822 I nnovation Park Dr., Oro Valley , AZ 85755.
8. Guidance for Industry : Pharmacokinetic s in Patients with I mpaired Renal Function 
Study  Design, Data Analy sis, and Impact on Dosing and Labeling. FDA Guidance,
March 2010.
